#  @BikeRieder BikeRieder🇨🇭 BikeRieder🇨🇭 posts on X about $arwr, novartis, arwr, discord the most. They currently have [-----] followers and [---] posts still getting attention that total [-------] engagements in the last [--] hours. ### Engagements: [-------] [#](/creator/twitter::862870446/interactions)  - [--] Week [-----] -71% - [--] Month [------] -18% - [--] Months [-------] +124% - [--] Year [-------] +171% ### Mentions: [--] [#](/creator/twitter::862870446/posts_active)  - [--] Months [--] +9.90% - [--] Year [---] +116% ### Followers: [-----] [#](/creator/twitter::862870446/followers)  - [--] Week [-----] no change - [--] Month [-----] +0.96% - [--] Months [-----] +13% - [--] Year [-----] +16% ### CreatorRank: [---------] [#](/creator/twitter::862870446/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [countries](/list/countries) [social networks](/list/social-networks) [exchanges](/list/exchanges) [currencies](/list/currencies) [cryptocurrencies](/list/cryptocurrencies) [travel destinations](/list/travel-destinations) [fashion brands](/list/fashion-brands) **Social topic influence** [$arwr](/topic/$arwr) #5, [novartis](/topic/novartis), [arwr](/topic/arwr), [discord](/topic/discord), [ceo](/topic/ceo), [$alny](/topic/$alny), [in the](/topic/in-the), [the first](/topic/the-first), [nasdaq](/topic/nasdaq), [$ions](/topic/$ions) **Top accounts mentioned or mentioned by** [@arrowheadpharma](/creator/undefined) [@bioboyscout](/creator/undefined) [@hall8jack](/creator/undefined) [@sonichedgefund](/creator/undefined) [@bionerd51](/creator/undefined) [@pawcio2009](/creator/undefined) [@marksharkking](/creator/undefined) [@rnaianalyst](/creator/undefined) [@leftyt75](/creator/undefined) [@biohazard3737](/creator/undefined) [@honegger](/creator/undefined) [@srfnews](/creator/undefined) [@lukecotton](/creator/undefined) [@jmuelle99](/creator/undefined) [@ionisdisrupts](/creator/undefined) [@scottjo88508204](/creator/undefined) [@chiragontwtr](/creator/undefined) [@3idwarrant](/creator/undefined) [@lsinnv](/creator/undefined) [@letmefireasap](/creator/undefined) **Top assets mentioned** [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Novartis AG (NVS)](/topic/novartis) [Alnylam Pharmaceuticals, Inc. (ALNY)](/topic/$alny) [Ionis Pharmaceuticals, Inc. Common Stock (IONS)](/topic/$ions) [Sarepta Therapeutics, Inc. (SRPT)](/topic/$srpt) [Sanofi (SNY)](/topic/sanofi) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Amgen, Inc. (AMGN)](/topic/$amgn) [Vera Therapeutics, Inc. (VERA)](/topic/$vera) [Pfizer, Inc. (PFE)](/topic/$pfe) ### Top Social Posts Top posts by engagements in the last [--] hours "$ARWR AMGN topline data ph2 OLPASIRAN: David M. Reese M.D. executive vice president R&D: "We are very ENTHUSIASTIC about these results and look forward to advancing olpasiran as a potential treatment for patients with elevated Lp(a). Phase [--] very soon https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-2-results-investigational https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-2-results-investigational" [X Link](https://x.com/BikeRieder/status/1531648198602792960) 2022-05-31T14:46Z [----] followers, [--] engagements "@sonichedgefund @Hall8Jack @Bionerd51 $ARWR To finish the speculation about the $200 million MS from srpt a2b_c2d (Thx) found the important news hidden in the SEC proxy's from [--] days ago. Market knows srpt has some balance sheet problems so our IR should put this info in a PR&@#%#" [X Link](https://x.com/BikeRieder/status/2016772457319833604) 2026-01-29T07:16Z [----] followers, [----] engagements "$ARWR Over [---] prescriptions for REDEMPLO have been received from a diverse prescriber base with geographically balanced uptake across the U.S.; Early patient starts fall into three categories: patients transitioning from our Expanded Access Program patients nave to the APOC3 class and patients switching from olezarsen; Patients receiving REDEMPLO include both clinically diagnosed and genetically confirmed FCS with the majority not required to submit genetic testing to gain access; https://twitter.com/i/web/status/2019519092051329475 https://twitter.com/i/web/status/2019519092051329475" [X Link](https://x.com/anyuser/status/2019519092051329475) 2026-02-05T21:10Z [----] followers, [----] engagements "$ARWR SP after offering (20%). One could interpret that investors find the dilution by new shares better than selling future profits (OlpaSiran to Royalty Pharma). -- Business dev. deals (partnerships) with non-core areas (liver and other) better than creative financing" [X Link](https://x.com/BikeRieder/status/1745398029291561157) 2024-01-11T10:51Z [----] followers, [----] engagements "$ALNY RNAi $ARWR Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact" [X Link](https://x.com/BikeRieder/status/2010699343636886009) 2026-01-12T13:04Z [----] followers, [----] engagements "$ALNY RNAi $ARWR ALNY down 8% this morning. One reason could be that they plan [--] extra hepatic tissue candidates "only" for [----] Still stuck in the liver Big difference with $ARWR BS $2'000'000'000 CNS sc muscle great obesity data lung phase [--] dimer in the clinic kidney big partnerships Novartis Amgen Takeda GSK SRPT phase [--] readout sHTG Q3/26 etc etc etc etc etc https://twitter.com/i/web/status/2010725715314966726 https://twitter.com/i/web/status/2010725715314966726" [X Link](https://x.com/BikeRieder/status/2010725715314966726) 2026-01-12T14:49Z [----] followers, [----] engagements "$ARWR FINALLY the first over $100 but still doesn't validate the PLATFORM COMPANY $ARWR PT raised to $110 at Piper $ARWR PT raised to $110 at Piper" [X Link](https://x.com/BikeRieder/status/2011065949886042282) 2026-01-13T13:21Z [----] followers, [----] engagements "$ARWR What is good for IONS is great for us. REDEMPLO is safer more effective and much cheaper" [X Link](https://x.com/BikeRieder/status/2011422531895603353) 2026-01-14T12:57Z [----] followers, [----] engagements "$ARWR News Drug Development [--] Next-Gen Candidates That Could Form the Future of Alzheimers https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment" [X Link](https://x.com/BikeRieder/status/2013247826969399348) 2026-01-19T13:51Z [----] followers, [----] engagements "Result: 1$ billion cash gratis" [X Link](https://x.com/BikeRieder/status/2014670665714970636) 2026-01-23T12:04Z [----] followers, [---] engagements "$ARWR Just to be clear the MS of $200 million is just earned but NOT received. Must be in tomorrow" [X Link](https://x.com/anyuser/status/2014718802059984998) 2026-01-23T15:16Z [----] followers, [----] engagements "@lukecotton__ We - ARWR - has the money and we can keep it" [X Link](https://x.com/BikeRieder/status/2014784015325163623) 2026-01-23T19:35Z [----] followers, [--] engagements "$ARWR Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia" [X Link](https://x.com/BikeRieder/status/2016128106868711728) 2026-01-27T12:36Z [----] followers, [----] engagements "$ARWR Arrowhead is at the forefront of innovation in the RNAi field and were proud of the versatile capabilities of our TRiM platform now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule said Chris Anzalone Ph.D. President and CEO at Arrowhead Pharmaceuticals. ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes which together have substantial clinical validation as important targets for reducing LDL-cholesterol triglycerides and total atherogenic lipoproteins. We see ARO-DIMER-PA as having the potential to" [X Link](https://x.com/BikeRieder/status/2016128716158488973) 2026-01-27T12:38Z [----] followers, [---] engagements "$ARWR STILL no PR about receiving the $200 million milestone payment but a new SEC filing. Doug Ingram CEO of $SRPT will no longer be a Board Member of our company Any implications for the deal Let's speculate" [X Link](https://x.com/anyuser/status/2016392689818665226) 2026-01-28T06:07Z [----] followers, [----] engagements "@Hall8Jack @Bionerd51 Yeah that's a good reason hopefully for SRPT that's the only one" [X Link](https://x.com/BikeRieder/status/2016471897920188690) 2026-01-28T11:22Z [----] followers, [---] engagements "@MarkSharkKing https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-issues-statement-on-the-status-of-its-ongoing-agreement-with-sarepta-therapeutics/ https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-issues-statement-on-the-status-of-its-ongoing-agreement-with-sarepta-therapeutics/" [X Link](https://x.com/BikeRieder/status/2016549700707532979) 2026-01-28T16:31Z [----] followers, [---] engagements "@sonichedgefund @Hall8Jack @Bionerd51 $ARWR You might be right and it's that simple PR for earning a MS but not upon receiving" [X Link](https://x.com/BikeRieder/status/2016584362561540566) 2026-01-28T18:49Z [----] followers, [---] engagements "$ARWR Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html" [X Link](https://x.com/anyuser/status/2017120924776923598) 2026-01-30T06:21Z [----] followers, [----] engagements "$ARWR From partimefriend on discord From Underdiagnosed to Under Control: PlozaSiran and Pharmacists Role in FCS and siRNAi's outlook in general https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs" [X Link](https://x.com/anyuser/status/2017519240719323574) 2026-01-31T08:44Z [----] followers, [----] engagements "$ARWR More and important information about our balance sheet from CFO 💰💰💰 Turning now to the balance sheet. Cash and investments totaled $917 million as of December [--] [----]. Common shares outstanding at quarter end were [-----] million. To be clear the reported cash balance does not include the $200 million that we earned for the DM1 second milestone which was received in January; nor does it include the $50 million anniversary payment that we expect to receive from Sarepta on or before February [--]. Finally and importantly the cash balance of $916 million also does not include the financing" [X Link](https://x.com/anyuser/status/2019751147007832122) 2026-02-06T12:32Z [----] followers, [---] engagements "$ARWR New data AROC3 in Patients https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1 https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1" [X Link](https://x.com/BikeRieder/status/1931019599299948660) 2025-06-06T16:05Z [----] followers, [----] engagements "$ARWR Analysis by grok - part [--] To compare Arrowhead Pharmaceuticals ARO-C3 (400 mg 41% proteinuria reduction after [--] months) with drug candidates from Otsuka and Vera Therapeutics for IgA nephropathy (IgAN) we can look at their respective candidates: Otsukas sibeprenlimab and Vera Therapeutics atacicept. Below is an analysis based on available data. Arrowhead Pharmaceuticals: ARO-C3 Mechanism: ARO-C3 is an RNA interference (RNAi) therapeutic designed to reduce liver production of complement component [--] (C3) targeting the complement pathway implicated in IgAN. Dosing: [---] mg subcutaneous" [X Link](https://x.com/BikeRieder/status/1931617649324167633) 2025-06-08T07:41Z [----] followers, [---] engagements "$ARWR Just a little reminder PR [--] days ago: PASADENA Calif.(BUSINESS WIRE)Nov. [--] [----] Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1 also called SRP-1003 an investigational RNA interference (RNAi) therapeutic for the treatment of type [--] myotonic dystrophy (DM1) the most common adult-onset muscular dystrophy. In accordance with the license and collaboration" [X Link](https://x.com/anyuser/status/2014644262000832929) 2026-01-23T10:19Z [----] followers, [----] engagements "Novartis sales of Leqvio (siRNAi IncliSiran) in 2025: $1.2 billion - blockbuster. About 240'000 patients Novartis preparing the medical system and patients for $ARWR cardio metabolic drugs PlozaSiran (REDEMPLO) ZodaSiran etc etc" [X Link](https://x.com/anyuser/status/2018949166739665277) 2026-02-04T07:26Z [----] followers, [----] engagements "IONS had $6 million revenue with TRYNGOLZA in their first full quarter (Q1/2025. Price is around $600'000 per year monthly dosing $50'000 per injection = [--] patients $ARWR REDEMPLO approved on November 18th [----] at a price of $60'000 per year [--] infections a year. So only about [--] weeks of sales possible. For [--] injection we go our first [---] patients Wonderful start https://twitter.com/i/web/status/2019518697635828064 https://twitter.com/i/web/status/2019518697635828064" [X Link](https://x.com/anyuser/status/2019518697635828064) 2026-02-05T21:09Z [----] followers, [----] engagements "$ARWR Financials for Q1/2025" [X Link](https://x.com/anyuser/status/2019520873749966895) 2026-02-05T21:17Z [----] followers, [----] engagements "@jmuelle99 I believe in $ARWRs scientists in Madison WI" [X Link](https://x.com/BikeRieder/status/790580750286544896) 2016-10-24T15:48Z [----] followers, [--] engagements "$ARWR eligible to receive approx. $1.6 bil in milestones for HBV license. Next possible payments [--] ph2b all ppl dosed $100mil [--] Fast Tr Breakthr Tr Accel Appr Prio Rev Reg Med each $100mil [--] start ph [--] $400mil [--] meeting primary endp $600mil [--] meeting sec ednp $200mil" [X Link](https://x.com/BikeRieder/status/1167020749825224704) 2019-08-29T10:26Z [----] followers, [--] engagements "@IonisDisrupts $ARWR Could be. But I think this would not be in our companys interest. CEO had huge interest to get the billions dropping in a regular rhythm from the start of phase 2b. But what do I know Was fun to think about it" [X Link](https://x.com/BikeRieder/status/1167158756658089984) 2019-08-29T19:35Z [----] followers, [--] engagements "$ARWR I would love to hear YMB Holden about the possible apportionment of those $1.6 billion HBV milestone payments from JNJ" [X Link](https://x.com/BikeRieder/status/1167161766738046978) 2019-08-29T19:47Z [----] followers, [--] engagements "$ARWR and AROANG3. Great target validation by $PFE thx $AKCA plan to report ph2 by mid [----]. By that time AROANG3 could be in pivotal phase 2/3. First to market again" [X Link](https://x.com/BikeRieder/status/1181302233029320705) 2019-10-07T20:16Z [----] followers, [--] engagements "$ARWR pic is from $Ions CC. Their subsidy $AKCA will report readouts on their Apoc3 and Ang3 ph [--] programs - like our company $ARWR also - this month Pro at ECS at the end of August. I dont fear this head to head comparison at all🎯🎯" [X Link](https://x.com/BikeRieder/status/1293440949369151489) 2020-08-12T06:55Z [----] followers, [--] engagements "@scottjo88508204 $ARWR He took the helm of an nanotech company in [----] (Arrowhead Research) to transform it - with some normal hiccups - in to a new little Amgen. [--] years of passion for a wonderful vision to come true now. There is a wonderful written article about that. https://www.lifescienceleader.com/doc/the-story-of-arrowhead-pharmaceuticals-adversity-odyssey-0001 https://www.lifescienceleader.com/doc/the-story-of-arrowhead-pharmaceuticals-adversity-odyssey-0001" [X Link](https://x.com/BikeRieder/status/1314845051575513090) 2020-10-10T08:27Z [----] followers, [--] engagements "$ARWR We Arrowheadians know that results in our phase [--] gives us data usually only achieved in phase 2b for most drugs. So this gives us the power to negotiate partnerships way earlier without loosing value. For me AROHSD -lot of interest (CEO) -and AROHIF2 are ready to partner" [X Link](https://x.com/BikeRieder/status/1400006692553871360) 2021-06-02T08:29Z [----] followers, [--] engagements "@chiragontwtr $ARWR Exactly We could see a partnership in the coming months" [X Link](https://x.com/BikeRieder/status/1455407974558617600) 2021-11-02T05:34Z [----] followers, [--] engagements "$ARWR Interview with CEO NVS today: What are the future MOA medicines: - cell therapy gen therapy siRNA Crispr base editing. Whats the acquisition strategy - smaller deals around $2 billions Whats your comment on rumors about buying $ALNY - no comment" [X Link](https://x.com/BikeRieder/status/1469644380092964869) 2021-12-11T12:24Z [----] followers, [--] engagements "$ARWR The global RNA interference (RNAi) drug delivery market reached a value of US$ [-----] Billion in [----]. Looking forward the publisher expects the market to reach US$ [------] Billion by [----] exhibiting a CAGR of 22.5% during 2022-2027. https://www.researchandmarkets.com/reports/5546995/rna-interference-rnai-drug-delivery-marketutm_source=GNOM&utm_medium=PressRelease&utm_code=phgg43&utm_campaign=1668649+-+Worldwide+RNA+Interference+(RNAi)+Drug+Delivery+Industry+to+2027+-+Players+Include+Alnylam+Pharmaceuticals%2c+Arrowhead+Pharmaceuticals+and+CureVac+Among+Others&utm_exec=jamu273prd$ARWR" [X Link](https://x.com/BikeRieder/status/1501191062446034944) 2022-03-08T13:40Z [----] followers, [--] engagements "$ARWR We're building RNAi "Holding" with RNAi platforms. Liver lung muscle CNS adipose. Soon more. Do we keep all platforms and partner only targets or do we sell entire platforms deals in the future Given capital we need [----] love to see muscle platform deal in June23" [X Link](https://x.com/BikeRieder/status/1666351493895581698) 2023-06-07T07:48Z [----] followers, [----] engagements "@3IDWarrant Not my opinion at all. We're not a DRNA twin. Much more potential here. DRNA was designed to be bought. We're designed to become a BP. That takes time. Rome was not built in a day. $ARWR" [X Link](https://x.com/BikeRieder/status/1666394732749021184) 2023-06-07T10:40Z [----] followers, [---] engagements "$ARWR THX to klastric on discord AROLPA now licensed to AMGN with the name OlpaSiran. Enrollment completion phase [--] (Ocean) in H1/2024 will trigger milestone payments from AMGN and Royalty Pharma. I assume all together $150 million💰💰" [X Link](https://x.com/BikeRieder/status/1745174518102970694) 2024-01-10T20:03Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-expanded-access-program https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-expanded-access-program" [X Link](https://x.com/BikeRieder/status/1772233938263474325) 2024-03-25T12:07Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy" [X Link](https://x.com/BikeRieder/status/1833468725447503936) 2024-09-10T11:33Z [----] followers, [----] engagements "$ARWR: 2nd one cash line was not right sorry I had some time on my hands and played around with some numbers after the great $SRPT - $ARWR deal I know it's very optimistic and certainly has some small errors but it's only about the macro and not the micro picture. CRAZY Numbers A lot of work for the Sarepta guys @ArrowheadPharma" [X Link](https://x.com/BikeRieder/status/1864650192084955543) 2024-12-05T12:37Z [----] followers, [----] engagements "$ARWR Retirement of Douglas Given at the end of [----]. We need a new Chairman for our Board. Why not Sarepta's CEO Douglas S. Ingram who will join the Board in Q1/2025 after closing of the ARWR-SRPT-Deal" [X Link](https://x.com/BikeRieder/status/1869350537575198932) 2024-12-18T11:54Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) for [--] new employees. At the end of Q1/2025 (FY) we have [---] employees who work for our RNAi powerhouse With anticipated [---] billion cash at the end of [----] it's looking great" [X Link](https://x.com/BikeRieder/status/1870945644883677219) 2024-12-22T21:32Z [----] followers, [----] engagements "$ARWR I'm honest I feel great gratification after NDA was FDA accepted and SRPT deal is closed now. Some ppl were so negative and claimed that ARWR management is not able to deliver NDA new partnerships RNAi extra hepatic manufacturing facility in Madison WI is a waste of money etc etc Now we have: _NDA FDA accepted for PlozaSiran _PlozaSiran approval is a given We fulfilled all first and secondary endpoints and had wonderful safety profile _Approval seeking in China / EU / other countries in [----] _Strong balance sheet - see above _$1.5 billion cash at hand a end of CY2025 _clear strategy" [X Link](https://x.com/BikeRieder/status/1881005624340750439) 2025-01-19T15:47Z [----] followers, [----] engagements "$ARWR Appointment of Douglas Ingram as a Director On February [--] [----] the Board of Directors of Arrowhead Pharmaceuticals Inc. (the Company) appointed Douglas Ingram as a director of the Company effective February [--] [----]. Mr. Ingrams appointment was pursuant to the Investor Rights Agreement between the Company and Sarepta Therapeutics Inc. (Sarepta) dated November [--] [----]. That means the $10 billion with SRPT is closed wonderful" [X Link](https://x.com/BikeRieder/status/1887823888677015699) 2025-02-07T11:21Z [----] followers, [----] engagements "$ARWR It looks like you're not familiar with the RNAi mechanism RNAi is a natural occurring pathway to silence genes causing diseases. Once you selected the right sequence preclinical results are transmitted in p1 to p3 In liver cells results are even better. James Hamilton said on a CC that's the same with obesity tissue" [X Link](https://x.com/BikeRieder/status/1894383492395368914) 2025-02-25T13:46Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals Announces Topline Results from Part [--] of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-topline-results-part-2-phase https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-topline-results-part-2-phase" [X Link](https://x.com/BikeRieder/status/1899064580644438098) 2025-03-10T11:47Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals to Participate in May [----] Investor Conferences" [X Link](https://x.com/BikeRieder/status/1920079370082820499) 2025-05-07T11:32Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals to Participate in June [----] Investor Conferences" [X Link](https://x.com/BikeRieder/status/1928071880587538696) 2025-05-29T12:52Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Initiates Phase [--] YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia Patients living with HoFH are difficult to adequately treat and have a very high risk of developing atherosclerotic cardiovascular disease due to severely elevated LDL-C often exceeding [---] mg/dL. As an RNAi-based therapeutic targeting ANGPTL3 investigational zodasiran has the potential to treat HoFH in a fundamentally different manner from traditional LDL-Clowering therapies said James Hamilton M.D. Chief Medical Officer and head of R&D" [X Link](https://x.com/BikeRieder/status/1942547822953292156) 2025-07-08T11:34Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics PASADENA Calif.--(BUSINESS WIRE)--Jul. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement and it expects Sarepta to continue to meet its required financial obligations. Sarepta has provided no indication of any intention to fail to" [X Link](https://x.com/BikeRieder/status/1947991395131674748) 2025-07-23T12:05Z [----] followers, [----] engagements "$ARWR OK thx to SRPT next "cracking point" for SRPT is $200 mil at the end of [----] and $50 mil in February [----]. Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics PASADENA Calif.--(BUSINESS WIRE)--Jul. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1 an" [X Link](https://x.com/BikeRieder/status/1949799189107351598) 2025-07-28T11:48Z [----] followers, [----] engagements "$ARWR Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics a majority-owned subsidiary of Arrowhead which was previously granted rights to investigational plozasiran in Greater China" [X Link](https://x.com/BikeRieder/status/1951231966130438240) 2025-08-01T10:42Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming September [----] Conferences Busy September with new data from OL trial PlozaSiran and ZodaSiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-september-2025 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-september-2025" [X Link](https://x.com/BikeRieder/status/1960668836832608429) 2025-08-27T11:40Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Upon closing Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA Arrowheads preclinical stage siRNA therapy for the treatment of synucleinopathies such as Parkinsons Disease plus additional collaboration targets https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-and-novartis-enter-global-license-and" [X Link](https://x.com/BikeRieder/status/1962841669939728894) 2025-09-02T11:34Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimers Disease and Other Tauopathies https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-requests-regulatory-clearance-0 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-requests-regulatory-clearance-0" [X Link](https://x.com/BikeRieder/status/1965740392546242702) 2025-09-10T11:33Z [----] followers, [----] engagements "$ARWR James Hamilton: ARO-MAPT is a potential treatment for Alzheimers disease designed to achieve delivery to deep brain regions after subcutaneous administration. Given the significant impact of Alzheimers disease additional disease-modifying therapies are severely needed. The tau protein which is the target of ARO-MAPT has strong correlation with symptom severity and is a promising therapeutic target for Alzheimers disease and other tauopathies said James Hamilton M.D. Chief Medical Officer and Head of R&D at Arrowhead. New preclinical data on the TRiM platform and ARO-MAPT being presented" [X Link](https://x.com/BikeRieder/status/1965743763902362102) 2025-09-10T11:46Z [----] followers, [----] engagements "$ARWR what's about that Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-complaint-declaratory-judgment https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-complaint-declaratory-judgment" [X Link](https://x.com/BikeRieder/status/1966102945923035591) 2025-09-11T11:34Z [----] followers, [---] engagements "$ARWR Upcoming event. Could be interesting" [X Link](https://x.com/BikeRieder/status/1967918941365551319) 2025-09-16T11:50Z [----] followers, [----] engagements "$ARWR Obesity presentation is out. Preclinical data no patients data - yet https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations" [X Link](https://x.com/BikeRieder/status/1968371402148593943) 2025-09-17T17:48Z [----] followers, [----] engagements "$ARWR Looking for a new job We have over [--] jobs openings. Beside others e.g. [--] rare disease specialists in our commercial department https://arrowheadpharma.com/careers/job-openings/ https://arrowheadpharma.com/careers/job-openings/" [X Link](https://x.com/BikeRieder/status/1970776827539980797) 2025-09-24T09:06Z [----] followers, [---] engagements "$ARWR More good News Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia CEO: Arrowhead is at the forefront of innovation in the RNAi field and the expansion of the TRiMTMplatform to now include a clinical stage candidate that can potentially silence expression of two genes in one RNAi molecule further reinforces our leadership position. ARO-DIMER-PA silences the PCSK9 and APOC3 genes which both together have substantial clinical validation as important targets for reducing LDL-cholesterol" [X Link](https://x.com/BikeRieder/status/1975525784149238138) 2025-10-07T11:37Z [----] followers, [----] engagements "$ARWR So $IONS has a drug candidate for ApoC-III in phase I and will take it to a phase [--]. Can't believe it it's a siRNA their first This candidate is years behind our siRNA PlozaSiran. This fact is a wonderful proof that they know TRYNGOLZA is an inferior drug for FCS and sHTG Another proof is their lawsuit and their platform change. Are ASO's an old tech Nice try IONS" [X Link](https://x.com/BikeRieder/status/1975546063030235618) 2025-10-07T12:57Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis PASADENA Calif.--(BUSINESS WIRE)--Oct. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis previously announced on September [--] [----] has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of [----] and other customary conditions. Summary of License and Collaboration Agreement Novartis received an" [X Link](https://x.com/BikeRieder/status/1980598500560978313) 2025-10-21T11:34Z [----] followers, [----] engagements "$ARWR Wow [--] new employees We are ready for the launch of PlozaSiran Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ir.arrowheadpharma.com/news-releases/news https://ir.arrowheadpharma.com/news-releases/news" [X Link](https://x.com/BikeRieder/status/1983427622580433391) 2025-10-29T06:56Z [----] followers, [---] engagements "$ARWR IONS reports $32 million net product sales of TRYNGOLZA in Q3 Last and their first Q was $19 million" [X Link](https://x.com/BikeRieder/status/1983494323124547713) 2025-10-29T11:21Z [----] followers, [----] engagements "$ARWR Novartis Q3 update from Novartis IncliSiran (Leqvio) Blockbuster in [----] $ARWR Inclisiran (Leqvio) a potent cholesterol-lowering agent byinhibiting PCSK9using siRNA. The first approved siRNA for lipid management. Look at Novartis and their projected sales in [----] Blockbuster This is the way our drug PlozaSiran will perform at least. Novartis https://t.co/0xm3T4sewq $ARWR Inclisiran (Leqvio) a potent cholesterol-lowering agent byinhibiting PCSK9using siRNA. The first approved siRNA for lipid management. Look at Novartis and their projected sales in [----] Blockbuster This is the way our" [X Link](https://x.com/BikeRieder/status/1983847195490357485) 2025-10-30T10:43Z [----] followers, [----] engagements "$ARWR Thx to divorceweiner on discord" [X Link](https://x.com/BikeRieder/status/1985679096559362325) 2025-11-04T12:02Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming November [----] Conferences Arrowhead Pharmaceuticals Inc. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2025 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2025" [X Link](https://x.com/BikeRieder/status/1985694716692689068) 2025-11-04T13:04Z [----] followers, [----] engagements "$ARWR What time does UPS deliver the mail from the FDA😉" [X Link](https://x.com/BikeRieder/status/1990458701191500086) 2025-11-17T16:35Z [----] followers, [----] engagements "$ARWR Started investing in [----] (pic). Now [--] years later (pic) at the age of [--] I wait for our first drug approval - of many to come in the future As you can see biotech investments can make you much older in a short time frame but also much richer" [X Link](https://x.com/BikeRieder/status/1990508675543265708) 2025-11-17T19:53Z [----] followers, 21.2K engagements "$ARWR Patient experience Ive had the pleasure to work with Arrowhead to get expanded access to Plozasiran. Its been life changing for my patient like a miracle drug. Maybe the most humbling experience Ive had in medicine to see a drug quickly cure a previously intractable disease. Congratulations Ive had the pleasure to work with Arrowhead to get expanded access to Plozasiran. Its been life changing for my patient like a miracle drug. Maybe the most humbling experience Ive had in medicine to see a drug quickly cure a previously intractable disease. Congratulations" [X Link](https://x.com/BikeRieder/status/1990853357842448827) 2025-11-18T18:43Z [----] followers, [----] engagements "$ARWR Some numbers from IONS: they reported $32 million in Q3/25 $19 million in Q2/25 and $7 million in the first Q after launch. TRYNGOLZA is available on a monthly basis ($50'000 $595'000 p.a.) So they had approximately [---] [---] and [--] patients on the drug in each Q. For me it doesn't make sense to take the medication only for one or only a few months. It's not a one and done thing. If you don't take it regularly you will be back to baseline and with that to possible AP. Could it be possible that patients subscribed it for a year If so we are down to [--] [--] respectively [--] patients. It makes" [X Link](https://x.com/BikeRieder/status/1991075987740610983) 2025-11-19T09:28Z [----] followers, [----] engagements "$ARWR CEO in great shape at Jeffries - worth to listen https://wsw.com/webcast/jeff332/register.aspxconf=jeff332&page=arwr&url=https%3A//wsw.com/webcast/jeff332/arwr/1866516 https://wsw.com/webcast/jeff332/register.aspxconf=jeff332&page=arwr&url=https%3A//wsw.com/webcast/jeff332/arwr/1866516" [X Link](https://x.com/BikeRieder/status/1991106982665978005) 2025-11-19T11:31Z [----] followers, [----] engagements "$ARWR Great overview from Wainwright -- thx to lolobelg at discord" [X Link](https://x.com/BikeRieder/status/1991122158324449360) 2025-11-19T12:31Z [----] followers, [----] engagements "$ARWR Just my reminder that prevalence of FCS might be much higher than we think [--] in a million and not [--] in a million. To those just include the clinical diagnosed patients Much bigger patient population. https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14986 https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14986" [X Link](https://x.com/BikeRieder/status/1991129285134815298) 2025-11-19T12:59Z [----] followers, [---] engagements "$ARWR ARORAGE: Great to see this Phase 2a is now online Thx to klastric on discord https://clinicaltrials.gov/study/NCT07241546term=arrowhead%20pharmaceuticals&aggFilters=status:act%20rec%20not&rank=9 ARO-RAGE is in phase [--] according to todays fda approval presentation. Website still says phase [--]. Is lung dead or not dead $arwr https://t.co/t94TrfhWmG https://clinicaltrials.gov/study/NCT07241546term=arrowhead%20pharmaceuticals&aggFilters=status:act%20rec%20not&rank=9 ARO-RAGE is in phase [--] according to todays fda approval presentation. Website still says phase [--]. Is lung dead or not dead" [X Link](https://x.com/BikeRieder/status/1992172259214020886) 2025-11-22T10:04Z [----] followers, [----] engagements "$ARWR Another $200 million to receive within [--] days. Good news just continue to keep going. $SRPT $ARWR Having achieved the pre-specified patient enrollment target a second milestone payment of USD$200 million will be made to Arrowhead Pharmaceuticals within [--] days. https://t.co/LBPWDzYcSL $SRPT $ARWR Having achieved the pre-specified patient enrollment target a second milestone payment of USD$200 million will be made to Arrowhead Pharmaceuticals within [--] days. https://t.co/LBPWDzYcSL" [X Link](https://x.com/BikeRieder/status/1992937450466050502) 2025-11-24T12:44Z [----] followers, [----] engagements "$ARWR Dr. Jennifer Hellawell summed up FDA approval of our therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) in one word: Exhilaration. For those with #FCS this milestone means hope a new potential therapy to help manage this #RareDisease https://t.co/7KGXpbFtB8 Dr. Jennifer Hellawell summed up FDA approval of our therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) in one word: Exhilaration. For those with #FCS this milestone means hope a new potential therapy to help manage this #RareDisease https://t.co/7KGXpbFtB8" [X Link](https://x.com/BikeRieder/status/1995511243717878181) 2025-12-01T15:12Z [----] followers, [----] engagements "$ARWR THX to tadmak on discord" [X Link](https://x.com/BikeRieder/status/1995586119266906467) 2025-12-01T20:09Z [----] followers, [---] engagements "$ARWR Very interesting presentations e.g. Title: A Monte Carlo Simulation Comparing TG Lowering with Plozasiran versus Olezarsan in Patients with FCS Presenter: Nihar Desai Others 👇" [X Link](https://x.com/BikeRieder/status/1995739116466569363) 2025-12-02T06:17Z [----] followers, [----] engagements "@RNAiAnalyst $ARWR They are eager to show the data. Words from last CC I'm not eager to present meager numbers" [X Link](https://x.com/BikeRieder/status/1996548052040183991) 2025-12-04T11:52Z [----] followers, [---] engagements "$ARWR Questions about the winner PlozaSiran versus Olezarsen NO https://ir.arrowheadpharma.com/static-files/a0dcc705-2870-4fae-bdf2-03cc588c08da https://ir.arrowheadpharma.com/static-files/a0dcc705-2870-4fae-bdf2-03cc588c08da" [X Link](https://x.com/BikeRieder/status/1997053724494385365) 2025-12-05T21:21Z [----] followers, [----] engagements "$ARWR TRiMTM platform for subcutaneous delivery of siRNA to Central Nervous System. We could get some new data at next week's 7th Annual CNS Delivery Summit Dec [--] 2025" [X Link](https://x.com/BikeRieder/status/1997581493561094222) 2025-12-07T08:18Z [----] followers, [----] engagements "@Hall8Jack @LSinnv $ARWR" [X Link](https://x.com/BikeRieder/status/1997784755065270274) 2025-12-07T21:46Z [----] followers, [---] engagements "$ARWR New corporate presentation available. Highlights: 🎯919 million cash not incl. $250 million from SRPT and another $200 million from Novartis coming in the next [--] months. 🎯TRiM - broadest and most versatile in RNAi field 🎯Delivering [--] cell types 🎯19 drug candidates 🎯🎯REDEMPLO label - NO contraindications NO warnings or precautions No adverse event profile 🎯very big market opportunities with REDEMPLO starting 2026/2027 https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations" [X Link](https://x.com/BikeRieder/status/1998705806762537408) 2025-12-10T10:46Z [----] followers, [----] engagements "$ARWR CNS summit presentation out https://ir.arrowheadpharma.com/static-files/61bc8b9b-ccf4-45d7-85ad-0d11825bdbc2 https://ir.arrowheadpharma.com/static-files/61bc8b9b-ccf4-45d7-85ad-0d11825bdbc2" [X Link](https://x.com/BikeRieder/status/1998766332427514101) 2025-12-10T14:46Z [----] followers, [----] engagements "$ARWR Some info about new candidate X (CNS / cardio metabolic) from jfez55 at discord- thx" [X Link](https://x.com/BikeRieder/status/1998782253132894422) 2025-12-10T15:49Z [----] followers, [----] engagements "@BioBoyScout $ARWR World class science 🎯💪" [X Link](https://x.com/BikeRieder/status/1999035828702503069) 2025-12-11T08:37Z [----] followers, [---] engagements "@BioBoyScout @LetMeFireASAP $ARWR Same with Lung platform same with Liver platform same with Adipose platform same with Muscle platform same with Cardio metabolic platform same with every new tissue platform" [X Link](https://x.com/BikeRieder/status/1999061765532107047) 2025-12-11T10:20Z [----] followers, [---] engagements "$ARWR What's about 2026" [X Link](https://x.com/BikeRieder/status/1999106778814918697) 2025-12-11T13:19Z [----] followers, [---] engagements "@tanavoi373 I have no clue about US tax law but that sounds pretty wonderful Where is this from $ARWR" [X Link](https://x.com/BikeRieder/status/1999372833047056715) 2025-12-12T06:56Z [----] followers, [---] engagements "$ARWR Wow. [--] new employees in October and now [--] PASADENA Calif.(BUSINESS WIRE)Dec. [--] [----] Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company on December [--] [----] the Companys Board of Directors approved inducement grants to [--] new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees in aggregate to receive up to [------] restricted stock units. The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years." [X Link](https://x.com/BikeRieder/status/2000913803593109626) 2025-12-16T13:00Z [----] followers, [----] engagements "$ARWR The first of many to come" [X Link](https://x.com/BikeRieder/status/2001268943235785065) 2025-12-17T12:31Z [----] followers, [----] engagements "$ARWR This is a perfect piece of journalism Every $ARWR investor should be forced to read it Thx @Denada670519 New on Substack (Free): $ARWR Pricing REDEMPLO as a Platform Not a One-Off Drug Why would Arrowhead price its first approved drug below traditional rare-disease norms This piece looks at REDEMPLOs $60K price as strategic sequencing not a mistake and what it signals about New on Substack (Free): $ARWR Pricing REDEMPLO as a Platform Not a One-Off Drug Why would Arrowhead price its first approved drug below traditional rare-disease norms This piece looks at REDEMPLOs $60K price as" [X Link](https://x.com/BikeRieder/status/2001755562069967177) 2025-12-18T20:44Z [----] followers, [----] engagements "$ARWR I expect SAD and MAD data INHBE and initial ALK7 data at the start of the new year. So BP knows the results and can stand in line for discussions and negotiations I some hidden room at JPM" [X Link](https://x.com/BikeRieder/status/2003208885864386876) 2025-12-22T20:59Z [----] followers, [----] engagements "$ARWR Not just a simple PR it's KOL webinar" [X Link](https://x.com/BikeRieder/status/2003446136095539537) 2025-12-23T12:42Z [----] followers, [---] engagements "$ARWR Again very well done. With that in mind it should be clear for everyone that RNAi at this stage is only at the beginning of a very long and successful journey. New on Substack: (Free) $ARWR Understanding Arrowheads TRiM Platform A practical guide to how Arrowhead builds RNAi medicines at scale This is a long-form explainer on Arrowheads TRiM platform. It walks through how TRiM is structured how it extends beyond the liver and why New on Substack: (Free) $ARWR Understanding Arrowheads TRiM Platform A practical guide to how Arrowhead builds RNAi medicines at scale This is a long-form" [X Link](https://x.com/BikeRieder/status/2008096443773387093) 2026-01-05T08:41Z [----] followers, [----] engagements "$ARWR Approval in Canada is leapfrogging competitor's TRYNGOLZA (IONS). REDEMPLO can be self administered at home $ARWR Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) https://t.co/QxlrbmkH8v $ARWR Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) https://t.co/QxlrbmkH8v" [X Link](https://x.com/BikeRieder/status/2008163939746517089) 2026-01-05T13:09Z [----] followers, [----] engagements "$ARWR Interim obesity data are out. Looks very good to me. Let the market decide" [X Link](https://x.com/BikeRieder/status/2008518351333847048) 2026-01-06T12:37Z [----] followers, [----] engagements "$ARWR Comparing WVE and ARWR data by grok from fredster at discord" [X Link](https://x.com/BikeRieder/status/2008522422094639448) 2026-01-06T12:53Z [----] followers, [----] engagements "$ARWR One more from partimefriend at discord too" [X Link](https://x.com/BikeRieder/status/2008524173480808815) 2026-01-06T13:00Z [----] followers, [---] engagements "$ARWR I remember James Hamilton saying that obesity tissue has liver like receptors. Now with ALK7 we have the proof of it Have in mind that delivering to the liver has been proven many times with several RNAi drugs approved" [X Link](https://x.com/BikeRieder/status/2008528673922854978) 2026-01-06T13:18Z [----] followers, [----] engagements "$ARWR Best and fastest drug candidate maker in the World The Shinkansen of the pharmaceutical industry. We are leaving the train station NOW🎯🚀 Most important our TriM platform is very safe" [X Link](https://x.com/BikeRieder/status/2008588786696102191) 2026-01-06T17:17Z [----] followers, [----] engagements "$ARWR More good News REDEMPLO APPROVAL IN CHINA" [X Link](https://x.com/BikeRieder/status/2008879579562422639) 2026-01-07T12:33Z [----] followers, [----] engagements "$ARWR CEO: NMPA approval of REDEMPLO for FCS in China is another positive step and continues the strong momentum since launching in the U.S. in November [----]. We look forward to working with Sanofi an innovative global company with an established presence in China said Christopher Anzalone Ph.D. President and CEO at Arrowhead Pharmaceuticals. We are happy to report encouraging initial response from physicians and patients following FDA approval and launch in the U.S. last month. We intend to continue building on this rapid progress and anticipate additional commercial launches in [----] pending" [X Link](https://x.com/BikeRieder/status/2008881583055327733) 2026-01-07T12:41Z [----] followers, [---] engagements "@LeftyT75 $ARWR Exactly why our company should be validated as a platform company. Once we have solved the tissue delivery specifications (liver muscle lung CNS adipose etc) it's easy and cheap scalable to dozens new drug candidates" [X Link](https://x.com/BikeRieder/status/2009904258011865480) 2026-01-10T08:24Z [----] followers, [---] engagements "$ARWR Expanding at a fast pace Again [--] positions open - including summer intern and 3rd shift in manufacturing. https://arrowheadpharma.com/careers/job-openings/ https://arrowheadpharma.com/careers/job-openings/" [X Link](https://x.com/BikeRieder/status/2010255979653595307) 2026-01-11T07:42Z [----] followers, [----] engagements "@BioBoyScout $ARWR Really impressed he did a very good job" [X Link](https://x.com/BikeRieder/status/2010806976461312164) 2026-01-12T20:11Z [----] followers, [---] engagements "$ARWR Thx to Quantumup at Stocktwits Piper Sandler $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS) and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and" [X Link](https://x.com/BikeRieder/status/2011068626384650589) 2026-01-13T13:31Z [----] followers, [---] engagements "$ARWR Now [--] jobs open" [X Link](https://x.com/BikeRieder/status/2011072689243672723) 2026-01-13T13:47Z [----] followers, [---] engagements "@grok @too_vez @Vivek4real_ It was always like that nothing new" [X Link](https://x.com/BikeRieder/status/2016483240614191171) 2026-01-28T12:07Z [----] followers, [--] engagements "@joey_pots @RNAiAnalyst The $ARWR HBV-Deal will be BIG These negotiations take more time. Soon in this theater" [X Link](https://x.com/BikeRieder/status/920997510210097152) 2017-10-19T12:58Z [----] followers, [--] engagements "Next catalysts for $ARWR: IND AMG-890 IND AMG-1 both with milestones 💰 💰 big collaboration extension with $AMGN on multiple targets partnership with one other BP IND ARO-ENaC. so stay tuned" [X Link](https://x.com/BikeRieder/status/1008965320202182656) 2018-06-19T06:50Z [----] followers, [--] engagements "$ARWR Still seeking an Alliance Manager on their website. Lets get him and make him busy with $JNJ $AMGN and NVS ROG et al Post $ALNY & their surprisingly modest $REGN deal attn rightfully pivots to Arrowheads 2nd gen TRiM platform (generally believed to have now surpassed Alnylams current platform efficacy). Powerful profitable alliances exist ( $JNJ $AMGN) w/elite BPs $ARWR got next. Post $ALNY & their surprisingly modest $REGN deal attn rightfully pivots to Arrowheads 2nd gen TRiM platform (generally believed to have now surpassed Alnylams current platform efficacy). Powerful profitable" [X Link](https://x.com/BikeRieder/status/1115451321518317569) 2019-04-09T03:08Z [----] followers, [--] engagements "$ARWR +17% Today WS celebrates Chris Anzalone CEO of the last [--] years. His business model is unbelievable strong. Much better than little IONS $DRNA +5%- dispersal of resources partnerships will slow co to BP pace - and [--] from $ALNY +5%. JM gave away $10 bil for some peanuts" [X Link](https://x.com/BikeRieder/status/1199067682718593026) 2019-11-25T20:49Z [----] followers, [--] engagements "$ARWR Thx Evolving123 on YMB. Good for $ARWR bulls bad for $IONS and $AKCA cult members" [X Link](https://x.com/BikeRieder/status/1220328227740246016) 2020-01-23T12:51Z [----] followers, [--] engagements "$ARWR I hope these results are the new gold standard for any trial against this disease. Every competitor - $vrtx - has to do pre and after treatment biopsies. Endpoints are monomer and polymer reductions at least. $ARWR AROAAT: Dear FDA what's next We got: - 97% red. in intra-hepatic Z-AAT polymer - 95% red. in intra-hepatic total Z-AAT burden - 66%/58% red. circulating ALT+GGT levels resp. - Up to 26% improv. in FibroScan values And this after only [--] doses $ARWR AROAAT: Dear FDA what's next We got: - 97% red. in intra-hepatic Z-AAT polymer - 95% red. in intra-hepatic total Z-AAT burden -" [X Link](https://x.com/BikeRieder/status/1306870674179477504) 2020-09-18T08:20Z [----] followers, [--] engagements "$ARWR VX [---] already a dead horse" [X Link](https://x.com/BikeRieder/status/1323366925469188097) 2020-11-02T20:50Z [----] followers, [--] engagements "$ARWR Novo Nordisk to acquire $DRNA for $39 Congrats longs RNAi is hot - again No rumors leaked before" [X Link](https://x.com/BikeRieder/status/1461307010008371200) 2021-11-18T12:15Z [----] followers, [--] engagements "@BioBoyScout $AMGN has [--] products on the market. Market cap of $ [---] billions. $NVS has [--] products on the market. Market cap of $ [---] billions $ALNY has [--] products on the market. Market cap of $ [--] billions. $ARWR RNAi TRiM" [X Link](https://x.com/BikeRieder/status/1664371917380370433) 2023-06-01T20:42Z [----] followers, [--] engagements "RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi partnerships to come Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk. $310m u/f to $ALNY. https://t.co/ivn2hZ12wr Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension" [X Link](https://x.com/BikeRieder/status/1683347647422164992) 2023-07-24T05:25Z [----] followers, [----] engagements "With this new partnership a BO of $ALNY by Novartis is off the table IMO $ARWR RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi partnerships to come RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi" [X Link](https://x.com/BikeRieder/status/1683456645253275649) 2023-07-24T12:38Z [----] followers, [----] engagements "$ARWR Reports inducement grants for [--] new employees. New total is around [---]. Financing announcements soon (partnership or royalty deal). https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-inducement-grants-under-22 $ARWR reports inducement grants for [--] new employees. That brings us to about [---] employees. Expanding fast. https://t.co/aCHRNcXScS https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-inducement-grants-under-22 $ARWR reports inducement grants for [--] new employees. That brings us to" [X Link](https://x.com/BikeRieder/status/1707247383481037164) 2023-09-28T04:14Z [----] followers, [----] engagements "$ARWR On October the 3rd the company announced to participate in a BMO fireside chat on October 10th. Still now link available on the website. Did they canceled it I expect a PR for the reason tomorrow" [X Link](https://x.com/BikeRieder/status/1712185406488207415) 2023-10-11T19:16Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals to Present New Phase [--] Clinical Data on Cardiometabolic Pipeline at AHA [----] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-new-phase-2-clinical-data https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-new-phase-2-clinical-data" [X Link](https://x.com/BikeRieder/status/1720041107080298650) 2023-11-02T11:32Z [----] followers, [----] engagements "$ARWR CEO: "As we are able to provide better clarity relating to the sources and magnitude of new capital I believe a clear overhang in our stock may be removed." With $350 mil cash today and planned expenditures $600 millions in [----] problem has to be solved next [--] months" [X Link](https://x.com/BikeRieder/status/1730159269725495554) 2023-11-30T09:38Z [----] followers, [----] engagements "@pawcio2009 Merry Christmas to you and your family you're my favorite at X for sure" [X Link](https://x.com/BikeRieder/status/1739023470158139758) 2023-12-24T20:41Z [----] followers, [---] engagements "$ARWR $450 mil offering was surprising to me Shareh. since [----] I saw all RS 10:1 offerings stopping DPC great $4.8 bil JNJ-deal: stock down 30% . Market like this minor offering bc we didn't gave away our most valuable CVD-assets Apoc3/ANG3 -JNJ lesson learned" [X Link](https://x.com/BikeRieder/status/1742642854013608040) 2024-01-03T20:23Z [----] followers, [----] engagements "$ARWR CC CFO about financing: "Even interest rates are higher the cost of debt is certainly lower than our cost of equity capital. It's an important part of non-dilutive financing". Exactly my view too. Our markets will be big giving e.g. 25% future gains of PlozaSiran is bad" [X Link](https://x.com/BikeRieder/status/1756266276446478743) 2024-02-10T10:38Z [----] followers, [----] engagements "$ARWR We have a new website: What is new to me is that we have [--] - two - phase 3's with PlozaSiran FCS and Hypertriglyceridemia Is that what was talked on last CC Patients pool is becoming bigger and bigger" [X Link](https://x.com/BikeRieder/status/1757770633847476244) 2024-02-14T14:15Z [----] followers, [----] engagements "@BioBoyScout $ARWR What could be the impact of that big increase of the patient pool" [X Link](https://x.com/BikeRieder/status/1770742561927205063) 2024-03-21T09:21Z [----] followers, [---] engagements "$ARWR Love market short time thinking. Couldn't resist to buy another 50K shares. NDA's starting this year. Expect [--] NDA every year from now. Expanding label for Ploza- and ZodaSiran. Wealth is made by patience not trading" [X Link](https://x.com/BikeRieder/status/1789018336602304736) 2024-05-10T19:43Z [----] followers, [----] engagements "$ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other lung cand. - dosing patients now. Just a matter of time market will recognize Vertex competitor. Cardio is absolute priority. Wouldn't surprise me to see vrtx partnering" [X Link](https://x.com/BikeRieder/status/1792888825976410430) 2024-05-21T12:03Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Presents New Phase [--] Data of Plozasiran in Patients with Mixed Hyperlipidemia https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-plozasiran" [X Link](https://x.com/BikeRieder/status/1795399776747352079) 2024-05-28T10:20Z [----] followers, [----] engagements "$ARWR with every day we are getting more intrinsic value Arrowhead Pharmaceuticals Presents New Phase [--] Data of Zodasiran in Patients with Mixed Hyperlipidemia https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-zodasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-zodasiran" [X Link](https://x.com/BikeRieder/status/1795751036248002868) 2024-05-29T09:36Z [----] followers, [----] engagements "$ARWR Busy month again Data C3 Arrowhead Pharmaceuticals to Participate in Upcoming June [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-june-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-june-2024" [X Link](https://x.com/BikeRieder/status/1796506227452854321) 2024-05-31T11:37Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase [--] CAPITAN Cardiovascular Outcomes Trial https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-advance-rnai-based-plozasiran-phase-3 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-advance-rnai-based-plozasiran-phase-3" [X Link](https://x.com/BikeRieder/status/1805663206532431951) 2024-06-25T18:03Z [----] followers, [----] engagements "$ARWR R&DDay pulmonary platform on July 16th. New data ARORAGE in asthma patients. Serum sRAGE up to 88% reduction and durable Wonderful safety profile. I remember an UBS analyst asking if 50% KD would be good enough. $ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other lung cand. - dosing patients now. Just a matter of time market will recognize Vertex competitor. Cardio is absolute priority. Wouldn't surprise me to see vrtx partnering $ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other" [X Link](https://x.com/BikeRieder/status/1813514806391161068) 2024-07-17T10:03Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals to Webcast Fiscal [----] Third Quarter Results on August [--] [----] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-fiscal-2024-third-quarter https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-fiscal-2024-third-quarter" [X Link](https://x.com/BikeRieder/status/1816078007267717532) 2024-07-24T11:48Z [----] followers, [---] engagements "$ARWR Its always good to take a step back and analyze. We will be a strong follower of Alnys success Besides the balance sheet my take is that CEO did a good job over the years. Im certain he will manage the balance sheet soon too" [X Link](https://x.com/BikeRieder/status/1818250891096371591) 2024-07-30T11:42Z [----] followers, [----] engagements "$ARWR CC PALISADE phase [--] with PlozaSiran Need some help" [X Link](https://x.com/BikeRieder/status/1831276405256032405) 2024-09-04T10:21Z [----] followers, [----] engagements "@Boarder31 @BioBoyScout I never pumped $ARWR I only expressed my vision of a future big biotech company" [X Link](https://x.com/BikeRieder/status/1842180113376419926) 2024-10-04T12:28Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming November [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2024" [X Link](https://x.com/BikeRieder/status/1853420521834070428) 2024-11-04T12:54Z [----] followers, [---] engagements "$ARWR Arrowhead Pharmaceuticals to Webcast [----] Fiscal Year End Results on November 26th https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results" [X Link](https://x.com/BikeRieder/status/1853779463156248657) 2024-11-05T12:40Z [----] followers, [---] engagements "$ARWR Months ago since CEO in public happy to hear him personally - first time ever at UBS Zrich He addressed honestly the big question market is waiting for a response: how do you pay for the big pipeline He was quite excited so deal soon with a Swiss giant NDA Nov24. $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp" [X Link](https://x.com/BikeRieder/status/1856580358902358089) 2024-11-13T06:10Z [----] followers, [----] engagements "$ARWR Great IDEA Big opportunity to reduce costs So let's stop [--] phase [--] PlozaSiran in patients with sHTG and Dyslipidemia bc our phase [--] in FCS (genetic and clinical diagnosed) patients was very successful My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead of one refusal to accept valid clinical results from other nations etc.). This stops patients from accessing promising therapies & raises prescription drug My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead" [X Link](https://x.com/BikeRieder/status/1857348871438901563) 2024-11-15T09:04Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase [--] Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase" [X Link](https://x.com/BikeRieder/status/1858491176917111204) 2024-11-18T12:43Z [----] followers, [---] engagements "$ARWR After listening to fireside chat at Jeffries I look forward to hear about a pulmonary platform deal with RAGE MUC5AC and MMP7 in coming weeks. https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations" [X Link](https://x.com/BikeRieder/status/1859167813996314777) 2024-11-20T09:32Z [----] followers, [----] engagements "$ARWR RNAi and we are still attractive for partnering Our CEO @ArrowheadPharma was hated by many with this Partnership he will be loved again. If he delivers with a great launch of PlozaSiran next year he will be everybody's darling. Patience payed https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and" [X Link](https://x.com/BikeRieder/status/1861394507901661417) 2024-11-26T13:00Z [----] followers, [----] engagements "$ARWR I admit I was never a fan of Sarepta and their DMD-drugs. But to advance ARWR's candidates under this collaboration I see it very positive Our other BP partner's are slow walking partners. SRPT has big interests to go fast" [X Link](https://x.com/BikeRieder/status/1861403047928185152) 2024-11-26T13:34Z [----] followers, [---] engagements "With [--] cand. deal $ARWR is eligible to receive dev. MS of between $110 mil and $410 mil per program and sales milestone payments of between $500 mil and $700 mil per PROGRAM. ARWR is also eligible to receive tiered royalties on commercial sales up to the low double digits💪💰💰" [X Link](https://x.com/BikeRieder/status/1861443390748991644) 2024-11-26T16:14Z [----] followers, [---] engagements "$ARWR Verona WI manufac/testing fac. successfully completed requirements to manufacture GMP drug substance to support US trials+other countries+ recently successf. completed QPaudit which allows internally produc. drug substance to be used in support o clinic programs in EU/UK" [X Link](https://x.com/BikeRieder/status/1861518789373788297) 2024-11-26T21:13Z [----] followers, [----] engagements "$ARWR Update SI" [X Link](https://x.com/BikeRieder/status/1861524901972066442) 2024-11-26T21:38Z [----] followers, [---] engagements "$ARWR ZODASIRAN alive" [X Link](https://x.com/BikeRieder/status/1861525500050510201) 2024-11-26T21:40Z [----] followers, [---] engagements "$ARWR Happy to see CVOT pushed back till more capital is available. TRiM platform machine is working hard to push more new candidates in clinic" [X Link](https://x.com/BikeRieder/status/1861530333625077958) 2024-11-26T21:59Z [----] followers, [----] engagements "$ARWR Capital available [---] billion Cash burn planned for [----] is [---] million. Cash at the end of 2025: 1billion 💰💰" [X Link](https://x.com/BikeRieder/status/1861533132987437395) 2024-11-26T22:10Z [----] followers, [---] engagements "$ARWR $SRPT My conclusions about risks and chances Summary of Programs under License and Collaboration Agreement Clinical Stage ARO-DUX4 which is designed to target the gene that encodes the DUX4 protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy type [--] currently dosing patients in a Phase 1/2 clinical study. ARO-DM1 which is designed to reduce expression of the dystrophia myotonica protein kinase or DMPK gene in skeletal muscle as a potential treatment for patients with type [--] myotonic dystrophy currently dosing patients in a Phase 1/2 clinical study." [X Link](https://x.com/BikeRieder/status/1861866094757044302) 2024-11-27T20:14Z [----] followers, [----] engagements "$ARWR More good News from PlozaSiran at AHA and TRIG-Forum More and more evidence that PlozaSiran will be a blockbuster drug. CEO: once in a lifetime opportunity https://www.triglycerideforum.org https://www.triglycerideforum.org" [X Link](https://x.com/BikeRieder/status/1862096475737457151) 2024-11-28T11:29Z [----] followers, [----] engagements "$ARWR Busy 2weeks Arrowhead Pharmaceuticals to Participate in Upcoming December [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024" [X Link](https://x.com/BikeRieder/status/1863564526232182955) 2024-12-02T12:43Z [----] followers, [---] engagements "$ARWR: I had some time on my hands and played around with some numbers after the great $SRPT - $ARWR deal I know it's very optimistic and certainly has some small errors but it's only about the macro and not the micro picture. CRAZY Numbers A lot of work for the Sarepta guys @ArrowheadPharma" [X Link](https://x.com/BikeRieder/status/1864631760098603452) 2024-12-05T11:23Z [----] followers, [---] engagements "$ARWR Exactly and let's keep in mind that INHBE is a liver target candidate. The TRiM liver platform is x time successfully proven (AAT OlpaSiran PlozaSiran and ZodaSiran) Clinical results were even better than pre clinical results So I expect the same for INHBE. ALK7 is targeting adipose tissue and James Hamilton said on one of the last CC that adipose tissue "acts " like the liver tissue. Easy to target with RNAi Can't wait to see trial results in 2025" [X Link](https://x.com/BikeRieder/status/1866059630280921316) 2024-12-09T09:57Z [----] followers, [---] engagements "$ARWR Developing siRNA for Neurodegenerative Diseases with very nice overview about RNAi and capabilities of TRiM platform https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187 https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187" [X Link](https://x.com/BikeRieder/status/1866747628865614254) 2024-12-11T07:31Z [----] followers, [---] engagements "$ARWR Title: PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) The APA/JPS/CAP/IAP [----] Joint Meeting Poster link: https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde" [X Link](https://x.com/BikeRieder/status/1866750461241594361) 2024-12-11T07:42Z [----] followers, [---] engagements "$ARWR 21st Global CVCT Forum Title: A Randomized Placebo-Controlled Phase [--] Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Data from subjects in an open-label extension trial - a Glimpse into [--] months results Presentation link: https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5 https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5" [X Link](https://x.com/BikeRieder/status/1866752445369684322) 2024-12-11T07:50Z [----] followers, [---] engagements "$ARWR Conclutions:" [X Link](https://x.com/BikeRieder/status/1866771220924133579) 2024-12-11T09:05Z [----] followers, [----] engagements "$ARWR Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb" [X Link](https://x.com/BikeRieder/status/1866823438285021308) 2024-12-11T12:32Z [----] followers, [----] engagements "$ARWR James Hamilton M.D. MBA Chief of Discovery and Translational Medicine at Arrowhead. ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose levels. These interim results in healthy volunteers give us confidence in the potential of ARO-CFB as we seek to complete Part [--] of the study over the coming months and subsequently look ahead to Part [--] of the study in patients with immunoglobulin A nephropathy which is the most common glomerular disease worldwide" [X Link](https://x.com/BikeRieder/status/1866823858818273507) 2024-12-11T12:34Z [----] followers, [---] engagements "The Swiss National Bank is lowering interest rates to 0.5% Inflation in Switzerland in November [----] was 0.7% compared to the same month last year. We live in the best country in the world bc we are not part of the EU but independent" [X Link](https://x.com/BikeRieder/status/1867137568716013653) 2024-12-12T09:21Z [----] followers, [---] engagements "$ARWR PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32 https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32" [X Link](https://x.com/BikeRieder/status/1867597142480802129) 2024-12-13T15:47Z [----] followers, [---] engagements "$ARWR And here the poster. https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c" [X Link](https://x.com/BikeRieder/status/1867597542772683166) 2024-12-13T15:48Z [----] followers, [---] engagements "$ARWR Conclusions" [X Link](https://x.com/BikeRieder/status/1867598262137762113) 2024-12-13T15:51Z [----] followers, [----] engagements "@BioBoyScout Ions without AP reduction label too $ARWR PlozaSiran had statistically significant AP reduction of 83%" [X Link](https://x.com/BikeRieder/status/1870112327753699757) 2024-12-20T14:21Z [----] followers, [---] engagements "$ARWR Some People have questioned the manufacturing and labor facility at Verona. CEO just perfectly planned it In December [----] the facility is planned to be ready and certified. Thx - again and again - to coldlander at discord: "scheduled to allow for the manufacture of GMP drug substance at the facility which is currently anticipated to begin by December 2024." This facility could turn into a future powerhouse for $ARWR in the light of RNAi future. #AMGN #Novartis et. al. CEO is a visionary" [X Link](https://x.com/BikeRieder/status/1870943847381111036) 2024-12-22T21:25Z [----] followers, [----] engagements "@pawcio2009 Happy new year to you and your family Thx for your work for the biotech community thx for your daily comments thx for your free honest and - politically - "incorrect" comments Love it" [X Link](https://x.com/BikeRieder/status/1874582666340970725) 2025-01-01T22:25Z [----] followers, [---] engagements "$ARWR PlozaSiran: Assuming company filed for geno- AND phenotype FCS patients and NDA is accepted in a few days. Does this mean that FDA is ready to approve PlozaSiran for both patient population in Q2/2025 PlozaSiran did meet all endpoint's in phase [--] Incl. statistical reduction of acute pancreatitis of 83% After IONS inferior drug olezarsen (branded as Tryngolza) approval a few days ago approval of PlozaSiran is a no brainer. So the patient population for ARWR should be at least 10x the patient population of IONS IONS extreme price tag is $595'000" [X Link](https://x.com/BikeRieder/status/1875659514411958617) 2025-01-04T21:44Z [----] followers, [----] engagements "$ARWR I may be wrong but IONS price tag of $595'000 for only genetic confirmed FCS patients without AP label is way too high. If you're the only seller of a new drug against FCS price might be OK. But with $ARWR superior drug (AP label dosing interval less drug more knock down better safety profile and maybe cheaper) coming on the market in just a few months patients and doctors may wait for PlozaSiran - I would wait for sure" [X Link](https://x.com/BikeRieder/status/1875863320982425753) 2025-01-05T11:14Z [----] followers, [---] engagements "$ARWR Genetic confirmed Familial chylomicronemia syndrome (FCS) has an estimated prevalence of 1/300000 (ranging from 1/100000 to 1/1000000 in Europe and North America). Let's take one third of world's population [---] billion. That will give around [----] patients. Clinically confirmed - phenotype - patients are around tenfold more. Let's assume we get [--] % of genotype FCS patients and [--] % of phenotype FCS patients. Genotype is ultra orphan so price could be $450'000. Phenotype is orphan price could be $100'000. Results: Genotype: $1124955000 Phenotype: $1'666'000'000 This is just playing around" [X Link](https://x.com/BikeRieder/status/1876001346370908421) 2025-01-05T20:22Z [----] followers, [---] engagements "$ARWR Don't forget that Severe hypercholesterolemia often defined as a LDL-C [---] mmol/L (193 mg/dL) confers 5-fold increased risk of developing ASCVD and is considered an indication for statin therapy in many national and international guidelines. Severe hypercholesterolemia affects 5% of the global population. Our [--] year phase [--] trial is almost fully enrolled. Readout in first have of [----]. sNDA soon afterwards" [X Link](https://x.com/BikeRieder/status/1876006699510956456) 2025-01-05T20:43Z [----] followers, [---] engagements "$ARWR YES FDA accepts our first NDA Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome We would like to thank all Arrowhead employees and the investigators patients and caregivers who contributed to the PALISADE Phase [--] study of plozasiran in patients with genetically confirmed or clinically diagnosed FCS said Chris Anzalone Ph.D. President and CEO at Arrowhead. Plozasiran has achieved promising and consistent results in various patient populations representing multiple points on the spectrum" [X Link](https://x.com/BikeRieder/status/1880385098429718794) 2025-01-17T22:41Z [----] followers, [----] engagements "GREAT deal between $ARWR and $SRPT is closed. Whats now (CEO at last CC): Now feel like all the pieces are in place to accelerate growth. We are confident that we will be ready for our potential first commercial launch in [----] provided we receive positive FDA approval. Strategy Balance sheet: See pinned tweet Cash runway extends into [----]. We will end CY25 with approx. $1.5 billion cash. In cardiometabolic area we're focusing resources (75%) as following: PlozaSiran is rapidly progressing toward commercial stage. NDA FDA accepted; PDUFA Nov. 18th We've begun leveraging outsourced resources" [X Link](https://x.com/BikeRieder/status/1887826644913574342) 2025-02-07T11:32Z [----] followers, [----] engagements "@biomannn @Varro_Analytics TRiM their RNAi platform was introduced in [----] only. Now we have our first NDA of several more to come in coming years. This tells me that this company is becoming a big biotech company. Bigger than alny $ARWR" [X Link](https://x.com/BikeRieder/status/1888334026353840357) 2025-02-08T21:08Z [----] followers, [---] engagements "$ARWR Confirmation💪💰💪💰 Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics Summary Financial Terms Upon closing Arrowhead receives a $500 millionupfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over [--] years. Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of" [X Link](https://x.com/BikeRieder/status/1888952860487876677) 2025-02-10T14:07Z [----] followers, [----] engagements "$ARWR JUST WOW Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity James Hamilton M.D. MBA Chief Medical Officer and Head of R&D. In preclinical studies in rodents and non-human primates ARO-ALK7 demonstrated dose-dependent and durable reductions in ALK7 mRNA expression in adipose tissue. Pharmacological studies in diet-induced obese mouse models demonstrate that ALK7 silencing in adipose tissue led to improved body composition with an approximate 50% reduction in fat mass with preservation of lean mass. Furthermore co-treatment of tirzepatide a GLP-1/GIP" [X Link](https://x.com/BikeRieder/status/1894365801945215228) 2025-02-25T12:36Z [----] followers, [----] engagements "@yaireinhorn $ARWR has no RNA editing candidate We are leading the RNAi extra hepatic field and we have a best in class RNAi platform" [X Link](https://x.com/BikeRieder/status/1901729235640705213) 2025-03-17T20:15Z [----] followers, [---] engagements "After today's SRPT disclosure of a patient's death on their gene therapy Elevidys I know why I like my RNAi platform company $ARWR so much RNAi is a natural occurring process in our body and therefore much lesser risky than a gene therapy. If there is a problem with RNAi - just stop taking the drug. I think also the market is looking at it that way. Sarepta's guidance for 2025: Doug Ingram president and chief executive officerSarepta Therapeutics. In [----] we intend to capitalize on our [----] achievements. In addition to [----] net product revenue guidance of$2.9 billionto$3.1 billion" [X Link](https://x.com/BikeRieder/status/1902083769538113707) 2025-03-18T19:44Z [----] followers, [----] engagements "$ARWR Results from our annual meeting" [X Link](https://x.com/BikeRieder/status/1902305630855070152) 2025-03-19T10:26Z [----] followers, [---] engagements "@ej23ny @BowTiedBiotech $ARWR AADT liver population is small Look at these numbers Big market Thanks to @BioBoyScout" [X Link](https://x.com/BikeRieder/status/1902317507257438551) 2025-03-19T11:13Z [----] followers, [---] engagements "RNAi $ARWR $ALNY Label: https://t.co/dDBqG08LJN $ALNY Label: https://t.co/dDBqG08LJN" [X Link](https://x.com/BikeRieder/status/1902850910402801873) 2025-03-20T22:33Z [----] followers, [----] engagements "$ARWR Market turmoil Irrational exaggeration in both directions Let's just keep cool and enjoy the last presentation about blockbuster PlozaSiran (Shasta [--] Muir) at: The American College of Cardiology (ACC) [----] March 29-2025 Chicago Illinois Turmoil at the new FDA bc of DOGE Not me I'm very optimistic that we will get our approval before PDUFA date November [--] [----] There are so many ppl working at the FDA just waiting to prove their efficiency and competence to the new administration" [X Link](https://x.com/BikeRieder/status/1909620825256607962) 2025-04-08T14:54Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@BikeRieder BikeRieder🇨🇭
BikeRieder🇨🇭 posts on X about $arwr, novartis, arwr, discord the most. They currently have [-----] followers and [---] posts still getting attention that total [-------] engagements in the last [--] hours.
Engagements: [-------] #
- [--] Week [-----] -71%
- [--] Month [------] -18%
- [--] Months [-------] +124%
- [--] Year [-------] +171%
Mentions: [--] #
- [--] Months [--] +9.90%
- [--] Year [---] +116%
Followers: [-----] #
- [--] Week [-----] no change
- [--] Month [-----] +0.96%
- [--] Months [-----] +13%
- [--] Year [-----] +16%
CreatorRank: [---------] #
Social Influence
Social category influence stocks finance countries social networks exchanges currencies cryptocurrencies travel destinations fashion brands
Social topic influence $arwr #5, novartis, arwr, discord, ceo, $alny, in the, the first, nasdaq, $ions
Top accounts mentioned or mentioned by @arrowheadpharma @bioboyscout @hall8jack @sonichedgefund @bionerd51 @pawcio2009 @marksharkking @rnaianalyst @leftyt75 @biohazard3737 @honegger @srfnews @lukecotton @jmuelle99 @ionisdisrupts @scottjo88508204 @chiragontwtr @3idwarrant @lsinnv @letmefireasap
Top assets mentioned Arrowhead Research Corporation (ARWR) Novartis AG (NVS) Alnylam Pharmaceuticals, Inc. (ALNY) Ionis Pharmaceuticals, Inc. Common Stock (IONS) Sarepta Therapeutics, Inc. (SRPT) Sanofi (SNY) Regeneron Pharmaceuticals Inc (REGN) Amgen, Inc. (AMGN) Vera Therapeutics, Inc. (VERA) Pfizer, Inc. (PFE)
Top Social Posts
Top posts by engagements in the last [--] hours
"$ARWR AMGN topline data ph2 OLPASIRAN: David M. Reese M.D. executive vice president R&D: "We are very ENTHUSIASTIC about these results and look forward to advancing olpasiran as a potential treatment for patients with elevated Lp(a). Phase [--] very soon https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-2-results-investigational https://investors.amgen.com/news-releases/news-release-details/amgen-announces-positive-topline-phase-2-results-investigational"
X Link 2022-05-31T14:46Z [----] followers, [--] engagements
"@sonichedgefund @Hall8Jack @Bionerd51 $ARWR To finish the speculation about the $200 million MS from srpt a2b_c2d (Thx) found the important news hidden in the SEC proxy's from [--] days ago. Market knows srpt has some balance sheet problems so our IR should put this info in a PR&@#%#"
X Link 2026-01-29T07:16Z [----] followers, [----] engagements
"$ARWR Over [---] prescriptions for REDEMPLO have been received from a diverse prescriber base with geographically balanced uptake across the U.S.; Early patient starts fall into three categories: patients transitioning from our Expanded Access Program patients nave to the APOC3 class and patients switching from olezarsen; Patients receiving REDEMPLO include both clinically diagnosed and genetically confirmed FCS with the majority not required to submit genetic testing to gain access; https://twitter.com/i/web/status/2019519092051329475 https://twitter.com/i/web/status/2019519092051329475"
X Link 2026-02-05T21:10Z [----] followers, [----] engagements
"$ARWR SP after offering (20%). One could interpret that investors find the dilution by new shares better than selling future profits (OlpaSiran to Royalty Pharma). -- Business dev. deals (partnerships) with non-core areas (liver and other) better than creative financing"
X Link 2024-01-11T10:51Z [----] followers, [----] engagements
"$ALNY RNAi $ARWR Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact https://www.businesswire.com/news/home/20260111699710/en/Alnylam-Launches-Alnylam-2030-Strategy-to-Drive-Next-Era-of-Growth-and-Patient-Impact"
X Link 2026-01-12T13:04Z [----] followers, [----] engagements
"$ALNY RNAi $ARWR ALNY down 8% this morning. One reason could be that they plan [--] extra hepatic tissue candidates "only" for [----] Still stuck in the liver Big difference with $ARWR BS $2'000'000'000 CNS sc muscle great obesity data lung phase [--] dimer in the clinic kidney big partnerships Novartis Amgen Takeda GSK SRPT phase [--] readout sHTG Q3/26 etc etc etc etc etc https://twitter.com/i/web/status/2010725715314966726 https://twitter.com/i/web/status/2010725715314966726"
X Link 2026-01-12T14:49Z [----] followers, [----] engagements
"$ARWR FINALLY the first over $100 but still doesn't validate the PLATFORM COMPANY $ARWR PT raised to $110 at Piper $ARWR PT raised to $110 at Piper"
X Link 2026-01-13T13:21Z [----] followers, [----] engagements
"$ARWR What is good for IONS is great for us. REDEMPLO is safer more effective and much cheaper"
X Link 2026-01-14T12:57Z [----] followers, [----] engagements
"$ARWR News Drug Development [--] Next-Gen Candidates That Could Form the Future of Alzheimers https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment https://www.biospace.com/drug-development/4-next-gen-candidates-that-could-form-the-future-of-alzheimers-treatment"
X Link 2026-01-19T13:51Z [----] followers, [----] engagements
"Result: 1$ billion cash gratis"
X Link 2026-01-23T12:04Z [----] followers, [---] engagements
"$ARWR Just to be clear the MS of $200 million is just earned but NOT received. Must be in tomorrow"
X Link 2026-01-23T15:16Z [----] followers, [----] engagements
"@lukecotton__ We - ARWR - has the money and we can keep it"
X Link 2026-01-23T19:35Z [----] followers, [--] engagements
"$ARWR Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia https://www.businesswire.com/news/home/20260127479152/en/Arrowhead-Pharmaceuticals-Initiates-Phase-12a-Study-of-ARO-DIMER-PA-the-First-Dual-Functional-RNAi-Therapeutic-for-the-Treatment-of-Mixed-Hyperlipidemia"
X Link 2026-01-27T12:36Z [----] followers, [----] engagements
"$ARWR Arrowhead is at the forefront of innovation in the RNAi field and were proud of the versatile capabilities of our TRiM platform now including the first-ever clinical candidate that can potentially silence expression of two genes in one RNAi molecule said Chris Anzalone Ph.D. President and CEO at Arrowhead Pharmaceuticals. ARO-DIMER-PA is designed to silence both the PCSK9 and APOC3 genes which together have substantial clinical validation as important targets for reducing LDL-cholesterol triglycerides and total atherogenic lipoproteins. We see ARO-DIMER-PA as having the potential to"
X Link 2026-01-27T12:38Z [----] followers, [---] engagements
"$ARWR STILL no PR about receiving the $200 million milestone payment but a new SEC filing. Doug Ingram CEO of $SRPT will no longer be a Board Member of our company Any implications for the deal Let's speculate"
X Link 2026-01-28T06:07Z [----] followers, [----] engagements
"@Hall8Jack @Bionerd51 Yeah that's a good reason hopefully for SRPT that's the only one"
X Link 2026-01-28T11:22Z [----] followers, [---] engagements
"@MarkSharkKing https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-issues-statement-on-the-status-of-its-ongoing-agreement-with-sarepta-therapeutics/ https://arrowheadpharma.com/news-press/arrowhead-pharmaceuticals-issues-statement-on-the-status-of-its-ongoing-agreement-with-sarepta-therapeutics/"
X Link 2026-01-28T16:31Z [----] followers, [---] engagements
"@sonichedgefund @Hall8Jack @Bionerd51 $ARWR You might be right and it's that simple PR for earning a MS but not upon receiving"
X Link 2026-01-28T18:49Z [----] followers, [---] engagements
"$ARWR Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html https://www.prnewswire.com/news-releases/longevity-biotech-stocks-surge-as-27-trillion-healthcare-shift-favors-cell-restoration-302674367.html"
X Link 2026-01-30T06:21Z [----] followers, [----] engagements
"$ARWR From partimefriend on discord From Underdiagnosed to Under Control: PlozaSiran and Pharmacists Role in FCS and siRNAi's outlook in general https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs https://www.pharmacytimes.com/view/from-underdiagnosed-to-under-control-plozasiran-and-pharmacists-role-in-fcs"
X Link 2026-01-31T08:44Z [----] followers, [----] engagements
"$ARWR More and important information about our balance sheet from CFO 💰💰💰 Turning now to the balance sheet. Cash and investments totaled $917 million as of December [--] [----]. Common shares outstanding at quarter end were [-----] million. To be clear the reported cash balance does not include the $200 million that we earned for the DM1 second milestone which was received in January; nor does it include the $50 million anniversary payment that we expect to receive from Sarepta on or before February [--]. Finally and importantly the cash balance of $916 million also does not include the financing"
X Link 2026-02-06T12:32Z [----] followers, [---] engagements
"$ARWR New data AROC3 in Patients https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1 https://ir.arrowheadpharma.com/static-files/71ace783-f6cd-47ac-b9a5-5809c13b70f1"
X Link 2025-06-06T16:05Z [----] followers, [----] engagements
"$ARWR Analysis by grok - part [--] To compare Arrowhead Pharmaceuticals ARO-C3 (400 mg 41% proteinuria reduction after [--] months) with drug candidates from Otsuka and Vera Therapeutics for IgA nephropathy (IgAN) we can look at their respective candidates: Otsukas sibeprenlimab and Vera Therapeutics atacicept. Below is an analysis based on available data. Arrowhead Pharmaceuticals: ARO-C3 Mechanism: ARO-C3 is an RNA interference (RNAi) therapeutic designed to reduce liver production of complement component [--] (C3) targeting the complement pathway implicated in IgAN. Dosing: [---] mg subcutaneous"
X Link 2025-06-08T07:41Z [----] followers, [---] engagements
"$ARWR Just a little reminder PR [--] days ago: PASADENA Calif.(BUSINESS WIRE)Nov. [--] [----] Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was earned when Arrowhead achieved the second development milestone event in a Phase 1/2 clinical study of ARO-DM1 also called SRP-1003 an investigational RNA interference (RNAi) therapeutic for the treatment of type [--] myotonic dystrophy (DM1) the most common adult-onset muscular dystrophy. In accordance with the license and collaboration"
X Link 2026-01-23T10:19Z [----] followers, [----] engagements
"Novartis sales of Leqvio (siRNAi IncliSiran) in 2025: $1.2 billion - blockbuster. About 240'000 patients Novartis preparing the medical system and patients for $ARWR cardio metabolic drugs PlozaSiran (REDEMPLO) ZodaSiran etc etc"
X Link 2026-02-04T07:26Z [----] followers, [----] engagements
"IONS had $6 million revenue with TRYNGOLZA in their first full quarter (Q1/2025. Price is around $600'000 per year monthly dosing $50'000 per injection = [--] patients $ARWR REDEMPLO approved on November 18th [----] at a price of $60'000 per year [--] infections a year. So only about [--] weeks of sales possible. For [--] injection we go our first [---] patients Wonderful start https://twitter.com/i/web/status/2019518697635828064 https://twitter.com/i/web/status/2019518697635828064"
X Link 2026-02-05T21:09Z [----] followers, [----] engagements
"$ARWR Financials for Q1/2025"
X Link 2026-02-05T21:17Z [----] followers, [----] engagements
"@jmuelle99 I believe in $ARWRs scientists in Madison WI"
X Link 2016-10-24T15:48Z [----] followers, [--] engagements
"$ARWR eligible to receive approx. $1.6 bil in milestones for HBV license. Next possible payments [--] ph2b all ppl dosed $100mil [--] Fast Tr Breakthr Tr Accel Appr Prio Rev Reg Med each $100mil [--] start ph [--] $400mil [--] meeting primary endp $600mil [--] meeting sec ednp $200mil"
X Link 2019-08-29T10:26Z [----] followers, [--] engagements
"@IonisDisrupts $ARWR Could be. But I think this would not be in our companys interest. CEO had huge interest to get the billions dropping in a regular rhythm from the start of phase 2b. But what do I know Was fun to think about it"
X Link 2019-08-29T19:35Z [----] followers, [--] engagements
"$ARWR I would love to hear YMB Holden about the possible apportionment of those $1.6 billion HBV milestone payments from JNJ"
X Link 2019-08-29T19:47Z [----] followers, [--] engagements
"$ARWR and AROANG3. Great target validation by $PFE thx $AKCA plan to report ph2 by mid [----]. By that time AROANG3 could be in pivotal phase 2/3. First to market again"
X Link 2019-10-07T20:16Z [----] followers, [--] engagements
"$ARWR pic is from $Ions CC. Their subsidy $AKCA will report readouts on their Apoc3 and Ang3 ph [--] programs - like our company $ARWR also - this month Pro at ECS at the end of August. I dont fear this head to head comparison at all🎯🎯"
X Link 2020-08-12T06:55Z [----] followers, [--] engagements
"@scottjo88508204 $ARWR He took the helm of an nanotech company in [----] (Arrowhead Research) to transform it - with some normal hiccups - in to a new little Amgen. [--] years of passion for a wonderful vision to come true now. There is a wonderful written article about that. https://www.lifescienceleader.com/doc/the-story-of-arrowhead-pharmaceuticals-adversity-odyssey-0001 https://www.lifescienceleader.com/doc/the-story-of-arrowhead-pharmaceuticals-adversity-odyssey-0001"
X Link 2020-10-10T08:27Z [----] followers, [--] engagements
"$ARWR We Arrowheadians know that results in our phase [--] gives us data usually only achieved in phase 2b for most drugs. So this gives us the power to negotiate partnerships way earlier without loosing value. For me AROHSD -lot of interest (CEO) -and AROHIF2 are ready to partner"
X Link 2021-06-02T08:29Z [----] followers, [--] engagements
"@chiragontwtr $ARWR Exactly We could see a partnership in the coming months"
X Link 2021-11-02T05:34Z [----] followers, [--] engagements
"$ARWR Interview with CEO NVS today: What are the future MOA medicines: - cell therapy gen therapy siRNA Crispr base editing. Whats the acquisition strategy - smaller deals around $2 billions Whats your comment on rumors about buying $ALNY - no comment"
X Link 2021-12-11T12:24Z [----] followers, [--] engagements
"$ARWR The global RNA interference (RNAi) drug delivery market reached a value of US$ [-----] Billion in [----]. Looking forward the publisher expects the market to reach US$ [------] Billion by [----] exhibiting a CAGR of 22.5% during 2022-2027. https://www.researchandmarkets.com/reports/5546995/rna-interference-rnai-drug-delivery-marketutm_source=GNOM&utm_medium=PressRelease&utm_code=phgg43&utm_campaign=1668649+-+Worldwide+RNA+Interference+(RNAi)+Drug+Delivery+Industry+to+2027+-+Players+Include+Alnylam+Pharmaceuticals%2c+Arrowhead+Pharmaceuticals+and+CureVac+Among+Others&utm_exec=jamu273prd$ARWR"
X Link 2022-03-08T13:40Z [----] followers, [--] engagements
"$ARWR We're building RNAi "Holding" with RNAi platforms. Liver lung muscle CNS adipose. Soon more. Do we keep all platforms and partner only targets or do we sell entire platforms deals in the future Given capital we need [----] love to see muscle platform deal in June23"
X Link 2023-06-07T07:48Z [----] followers, [----] engagements
"@3IDWarrant Not my opinion at all. We're not a DRNA twin. Much more potential here. DRNA was designed to be bought. We're designed to become a BP. That takes time. Rome was not built in a day. $ARWR"
X Link 2023-06-07T10:40Z [----] followers, [---] engagements
"$ARWR THX to klastric on discord AROLPA now licensed to AMGN with the name OlpaSiran. Enrollment completion phase [--] (Ocean) in H1/2024 will trigger milestone payments from AMGN and Royalty Pharma. I assume all together $150 million💰💰"
X Link 2024-01-10T20:03Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-expanded-access-program https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-initiates-expanded-access-program"
X Link 2024-03-25T12:07Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-receives-fda-breakthrough-therapy"
X Link 2024-09-10T11:33Z [----] followers, [----] engagements
"$ARWR: 2nd one cash line was not right sorry I had some time on my hands and played around with some numbers after the great $SRPT - $ARWR deal I know it's very optimistic and certainly has some small errors but it's only about the macro and not the micro picture. CRAZY Numbers A lot of work for the Sarepta guys @ArrowheadPharma"
X Link 2024-12-05T12:37Z [----] followers, [----] engagements
"$ARWR Retirement of Douglas Given at the end of [----]. We need a new Chairman for our Board. Why not Sarepta's CEO Douglas S. Ingram who will join the Board in Q1/2025 after closing of the ARWR-SRPT-Deal"
X Link 2024-12-18T11:54Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) for [--] new employees. At the end of Q1/2025 (FY) we have [---] employees who work for our RNAi powerhouse With anticipated [---] billion cash at the end of [----] it's looking great"
X Link 2024-12-22T21:32Z [----] followers, [----] engagements
"$ARWR I'm honest I feel great gratification after NDA was FDA accepted and SRPT deal is closed now. Some ppl were so negative and claimed that ARWR management is not able to deliver NDA new partnerships RNAi extra hepatic manufacturing facility in Madison WI is a waste of money etc etc Now we have: _NDA FDA accepted for PlozaSiran _PlozaSiran approval is a given We fulfilled all first and secondary endpoints and had wonderful safety profile _Approval seeking in China / EU / other countries in [----] _Strong balance sheet - see above _$1.5 billion cash at hand a end of CY2025 _clear strategy"
X Link 2025-01-19T15:47Z [----] followers, [----] engagements
"$ARWR Appointment of Douglas Ingram as a Director On February [--] [----] the Board of Directors of Arrowhead Pharmaceuticals Inc. (the Company) appointed Douglas Ingram as a director of the Company effective February [--] [----]. Mr. Ingrams appointment was pursuant to the Investor Rights Agreement between the Company and Sarepta Therapeutics Inc. (Sarepta) dated November [--] [----]. That means the $10 billion with SRPT is closed wonderful"
X Link 2025-02-07T11:21Z [----] followers, [----] engagements
"$ARWR It looks like you're not familiar with the RNAi mechanism RNAi is a natural occurring pathway to silence genes causing diseases. Once you selected the right sequence preclinical results are transmitted in p1 to p3 In liver cells results are even better. James Hamilton said on a CC that's the same with obesity tissue"
X Link 2025-02-25T13:46Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals Announces Topline Results from Part [--] of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-topline-results-part-2-phase https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-topline-results-part-2-phase"
X Link 2025-03-10T11:47Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals to Participate in May [----] Investor Conferences"
X Link 2025-05-07T11:32Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals to Participate in June [----] Investor Conferences"
X Link 2025-05-29T12:52Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Initiates Phase [--] YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia Patients living with HoFH are difficult to adequately treat and have a very high risk of developing atherosclerotic cardiovascular disease due to severely elevated LDL-C often exceeding [---] mg/dL. As an RNAi-based therapeutic targeting ANGPTL3 investigational zodasiran has the potential to treat HoFH in a fundamentally different manner from traditional LDL-Clowering therapies said James Hamilton M.D. Chief Medical Officer and head of R&D"
X Link 2025-07-08T11:34Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics PASADENA Calif.--(BUSINESS WIRE)--Jul. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today issued a statement to address questions about the status of its ongoing Exclusive License and Collaboration Agreement with Sarepta Therapeutics. Arrowhead continues to conduct clinical and non-clinical studies as stipulated in the agreement and it expects Sarepta to continue to meet its required financial obligations. Sarepta has provided no indication of any intention to fail to"
X Link 2025-07-23T12:05Z [----] followers, [----] engagements
"$ARWR OK thx to SRPT next "cracking point" for SRPT is $200 mil at the end of [----] and $50 mil in February [----]. Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics PASADENA Calif.--(BUSINESS WIRE)--Jul. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that it has earned a $100 million milestone payment from Sarepta Therapeutics (NASDAQ: SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1 an"
X Link 2025-07-28T11:48Z [----] followers, [----] engagements
"$ARWR Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics a majority-owned subsidiary of Arrowhead which was previously granted rights to investigational plozasiran in Greater China"
X Link 2025-08-01T10:42Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming September [----] Conferences Busy September with new data from OL trial PlozaSiran and ZodaSiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-september-2025 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-september-2025"
X Link 2025-08-27T11:40Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement - Upon closing Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA Arrowheads preclinical stage siRNA therapy for the treatment of synucleinopathies such as Parkinsons Disease plus additional collaboration targets https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-and-novartis-enter-global-license-and"
X Link 2025-09-02T11:34Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimers Disease and Other Tauopathies https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-requests-regulatory-clearance-0 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-requests-regulatory-clearance-0"
X Link 2025-09-10T11:33Z [----] followers, [----] engagements
"$ARWR James Hamilton: ARO-MAPT is a potential treatment for Alzheimers disease designed to achieve delivery to deep brain regions after subcutaneous administration. Given the significant impact of Alzheimers disease additional disease-modifying therapies are severely needed. The tau protein which is the target of ARO-MAPT has strong correlation with symptom severity and is a promising therapeutic target for Alzheimers disease and other tauopathies said James Hamilton M.D. Chief Medical Officer and Head of R&D at Arrowhead. New preclinical data on the TRiM platform and ARO-MAPT being presented"
X Link 2025-09-10T11:46Z [----] followers, [----] engagements
"$ARWR what's about that Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-complaint-declaratory-judgment https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-files-complaint-declaratory-judgment"
X Link 2025-09-11T11:34Z [----] followers, [---] engagements
"$ARWR Upcoming event. Could be interesting"
X Link 2025-09-16T11:50Z [----] followers, [----] engagements
"$ARWR Obesity presentation is out. Preclinical data no patients data - yet https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations"
X Link 2025-09-17T17:48Z [----] followers, [----] engagements
"$ARWR Looking for a new job We have over [--] jobs openings. Beside others e.g. [--] rare disease specialists in our commercial department https://arrowheadpharma.com/careers/job-openings/ https://arrowheadpharma.com/careers/job-openings/"
X Link 2025-09-24T09:06Z [----] followers, [---] engagements
"$ARWR More good News Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia CEO: Arrowhead is at the forefront of innovation in the RNAi field and the expansion of the TRiMTMplatform to now include a clinical stage candidate that can potentially silence expression of two genes in one RNAi molecule further reinforces our leadership position. ARO-DIMER-PA silences the PCSK9 and APOC3 genes which both together have substantial clinical validation as important targets for reducing LDL-cholesterol"
X Link 2025-10-07T11:37Z [----] followers, [----] engagements
"$ARWR So $IONS has a drug candidate for ApoC-III in phase I and will take it to a phase [--]. Can't believe it it's a siRNA their first This candidate is years behind our siRNA PlozaSiran. This fact is a wonderful proof that they know TRYNGOLZA is an inferior drug for FCS and sHTG Another proof is their lawsuit and their platform change. Are ASO's an old tech Nice try IONS"
X Link 2025-10-07T12:57Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis PASADENA Calif.--(BUSINESS WIRE)--Oct. [--] 2025-- Arrowhead Pharmaceuticals Inc.(NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis previously announced on September [--] [----] has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of [----] and other customary conditions. Summary of License and Collaboration Agreement Novartis received an"
X Link 2025-10-21T11:34Z [----] followers, [----] engagements
"$ARWR Wow [--] new employees We are ready for the launch of PlozaSiran Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://ir.arrowheadpharma.com/news-releases/news https://ir.arrowheadpharma.com/news-releases/news"
X Link 2025-10-29T06:56Z [----] followers, [---] engagements
"$ARWR IONS reports $32 million net product sales of TRYNGOLZA in Q3 Last and their first Q was $19 million"
X Link 2025-10-29T11:21Z [----] followers, [----] engagements
"$ARWR Novartis Q3 update from Novartis IncliSiran (Leqvio) Blockbuster in [----] $ARWR Inclisiran (Leqvio) a potent cholesterol-lowering agent byinhibiting PCSK9using siRNA. The first approved siRNA for lipid management. Look at Novartis and their projected sales in [----] Blockbuster This is the way our drug PlozaSiran will perform at least. Novartis https://t.co/0xm3T4sewq $ARWR Inclisiran (Leqvio) a potent cholesterol-lowering agent byinhibiting PCSK9using siRNA. The first approved siRNA for lipid management. Look at Novartis and their projected sales in [----] Blockbuster This is the way our"
X Link 2025-10-30T10:43Z [----] followers, [----] engagements
"$ARWR Thx to divorceweiner on discord"
X Link 2025-11-04T12:02Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming November [----] Conferences Arrowhead Pharmaceuticals Inc. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2025 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2025"
X Link 2025-11-04T13:04Z [----] followers, [----] engagements
"$ARWR What time does UPS deliver the mail from the FDA😉"
X Link 2025-11-17T16:35Z [----] followers, [----] engagements
"$ARWR Started investing in [----] (pic). Now [--] years later (pic) at the age of [--] I wait for our first drug approval - of many to come in the future As you can see biotech investments can make you much older in a short time frame but also much richer"
X Link 2025-11-17T19:53Z [----] followers, 21.2K engagements
"$ARWR Patient experience Ive had the pleasure to work with Arrowhead to get expanded access to Plozasiran. Its been life changing for my patient like a miracle drug. Maybe the most humbling experience Ive had in medicine to see a drug quickly cure a previously intractable disease. Congratulations Ive had the pleasure to work with Arrowhead to get expanded access to Plozasiran. Its been life changing for my patient like a miracle drug. Maybe the most humbling experience Ive had in medicine to see a drug quickly cure a previously intractable disease. Congratulations"
X Link 2025-11-18T18:43Z [----] followers, [----] engagements
"$ARWR Some numbers from IONS: they reported $32 million in Q3/25 $19 million in Q2/25 and $7 million in the first Q after launch. TRYNGOLZA is available on a monthly basis ($50'000 $595'000 p.a.) So they had approximately [---] [---] and [--] patients on the drug in each Q. For me it doesn't make sense to take the medication only for one or only a few months. It's not a one and done thing. If you don't take it regularly you will be back to baseline and with that to possible AP. Could it be possible that patients subscribed it for a year If so we are down to [--] [--] respectively [--] patients. It makes"
X Link 2025-11-19T09:28Z [----] followers, [----] engagements
"$ARWR CEO in great shape at Jeffries - worth to listen https://wsw.com/webcast/jeff332/register.aspxconf=jeff332&page=arwr&url=https%3A//wsw.com/webcast/jeff332/arwr/1866516 https://wsw.com/webcast/jeff332/register.aspxconf=jeff332&page=arwr&url=https%3A//wsw.com/webcast/jeff332/arwr/1866516"
X Link 2025-11-19T11:31Z [----] followers, [----] engagements
"$ARWR Great overview from Wainwright -- thx to lolobelg at discord"
X Link 2025-11-19T12:31Z [----] followers, [----] engagements
"$ARWR Just my reminder that prevalence of FCS might be much higher than we think [--] in a million and not [--] in a million. To those just include the clinical diagnosed patients Much bigger patient population. https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14986 https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14986"
X Link 2025-11-19T12:59Z [----] followers, [---] engagements
"$ARWR ARORAGE: Great to see this Phase 2a is now online Thx to klastric on discord https://clinicaltrials.gov/study/NCT07241546term=arrowhead%20pharmaceuticals&aggFilters=status:act%20rec%20not&rank=9 ARO-RAGE is in phase [--] according to todays fda approval presentation. Website still says phase [--]. Is lung dead or not dead $arwr https://t.co/t94TrfhWmG https://clinicaltrials.gov/study/NCT07241546term=arrowhead%20pharmaceuticals&aggFilters=status:act%20rec%20not&rank=9 ARO-RAGE is in phase [--] according to todays fda approval presentation. Website still says phase [--]. Is lung dead or not dead"
X Link 2025-11-22T10:04Z [----] followers, [----] engagements
"$ARWR Another $200 million to receive within [--] days. Good news just continue to keep going. $SRPT $ARWR Having achieved the pre-specified patient enrollment target a second milestone payment of USD$200 million will be made to Arrowhead Pharmaceuticals within [--] days. https://t.co/LBPWDzYcSL $SRPT $ARWR Having achieved the pre-specified patient enrollment target a second milestone payment of USD$200 million will be made to Arrowhead Pharmaceuticals within [--] days. https://t.co/LBPWDzYcSL"
X Link 2025-11-24T12:44Z [----] followers, [----] engagements
"$ARWR Dr. Jennifer Hellawell summed up FDA approval of our therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) in one word: Exhilaration. For those with #FCS this milestone means hope a new potential therapy to help manage this #RareDisease https://t.co/7KGXpbFtB8 Dr. Jennifer Hellawell summed up FDA approval of our therapy to lower triglycerides in adults with Familial Chylomicronemia Syndrome (FCS) in one word: Exhilaration. For those with #FCS this milestone means hope a new potential therapy to help manage this #RareDisease https://t.co/7KGXpbFtB8"
X Link 2025-12-01T15:12Z [----] followers, [----] engagements
"$ARWR THX to tadmak on discord"
X Link 2025-12-01T20:09Z [----] followers, [---] engagements
"$ARWR Very interesting presentations e.g. Title: A Monte Carlo Simulation Comparing TG Lowering with Plozasiran versus Olezarsan in Patients with FCS Presenter: Nihar Desai Others 👇"
X Link 2025-12-02T06:17Z [----] followers, [----] engagements
"@RNAiAnalyst $ARWR They are eager to show the data. Words from last CC I'm not eager to present meager numbers"
X Link 2025-12-04T11:52Z [----] followers, [---] engagements
"$ARWR Questions about the winner PlozaSiran versus Olezarsen NO https://ir.arrowheadpharma.com/static-files/a0dcc705-2870-4fae-bdf2-03cc588c08da https://ir.arrowheadpharma.com/static-files/a0dcc705-2870-4fae-bdf2-03cc588c08da"
X Link 2025-12-05T21:21Z [----] followers, [----] engagements
"$ARWR TRiMTM platform for subcutaneous delivery of siRNA to Central Nervous System. We could get some new data at next week's 7th Annual CNS Delivery Summit Dec [--] 2025"
X Link 2025-12-07T08:18Z [----] followers, [----] engagements
"@Hall8Jack @LSinnv $ARWR"
X Link 2025-12-07T21:46Z [----] followers, [---] engagements
"$ARWR New corporate presentation available. Highlights: 🎯919 million cash not incl. $250 million from SRPT and another $200 million from Novartis coming in the next [--] months. 🎯TRiM - broadest and most versatile in RNAi field 🎯Delivering [--] cell types 🎯19 drug candidates 🎯🎯REDEMPLO label - NO contraindications NO warnings or precautions No adverse event profile 🎯very big market opportunities with REDEMPLO starting 2026/2027 https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations"
X Link 2025-12-10T10:46Z [----] followers, [----] engagements
"$ARWR CNS summit presentation out https://ir.arrowheadpharma.com/static-files/61bc8b9b-ccf4-45d7-85ad-0d11825bdbc2 https://ir.arrowheadpharma.com/static-files/61bc8b9b-ccf4-45d7-85ad-0d11825bdbc2"
X Link 2025-12-10T14:46Z [----] followers, [----] engagements
"$ARWR Some info about new candidate X (CNS / cardio metabolic) from jfez55 at discord- thx"
X Link 2025-12-10T15:49Z [----] followers, [----] engagements
"@BioBoyScout $ARWR World class science 🎯💪"
X Link 2025-12-11T08:37Z [----] followers, [---] engagements
"@BioBoyScout @LetMeFireASAP $ARWR Same with Lung platform same with Liver platform same with Adipose platform same with Muscle platform same with Cardio metabolic platform same with every new tissue platform"
X Link 2025-12-11T10:20Z [----] followers, [---] engagements
"$ARWR What's about 2026"
X Link 2025-12-11T13:19Z [----] followers, [---] engagements
"@tanavoi373 I have no clue about US tax law but that sounds pretty wonderful Where is this from $ARWR"
X Link 2025-12-12T06:56Z [----] followers, [---] engagements
"$ARWR Wow. [--] new employees in October and now [--] PASADENA Calif.(BUSINESS WIRE)Dec. [--] [----] Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company on December [--] [----] the Companys Board of Directors approved inducement grants to [--] new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees in aggregate to receive up to [------] restricted stock units. The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years."
X Link 2025-12-16T13:00Z [----] followers, [----] engagements
"$ARWR The first of many to come"
X Link 2025-12-17T12:31Z [----] followers, [----] engagements
"$ARWR This is a perfect piece of journalism Every $ARWR investor should be forced to read it Thx @Denada670519 New on Substack (Free): $ARWR Pricing REDEMPLO as a Platform Not a One-Off Drug Why would Arrowhead price its first approved drug below traditional rare-disease norms This piece looks at REDEMPLOs $60K price as strategic sequencing not a mistake and what it signals about New on Substack (Free): $ARWR Pricing REDEMPLO as a Platform Not a One-Off Drug Why would Arrowhead price its first approved drug below traditional rare-disease norms This piece looks at REDEMPLOs $60K price as"
X Link 2025-12-18T20:44Z [----] followers, [----] engagements
"$ARWR I expect SAD and MAD data INHBE and initial ALK7 data at the start of the new year. So BP knows the results and can stand in line for discussions and negotiations I some hidden room at JPM"
X Link 2025-12-22T20:59Z [----] followers, [----] engagements
"$ARWR Not just a simple PR it's KOL webinar"
X Link 2025-12-23T12:42Z [----] followers, [---] engagements
"$ARWR Again very well done. With that in mind it should be clear for everyone that RNAi at this stage is only at the beginning of a very long and successful journey. New on Substack: (Free) $ARWR Understanding Arrowheads TRiM Platform A practical guide to how Arrowhead builds RNAi medicines at scale This is a long-form explainer on Arrowheads TRiM platform. It walks through how TRiM is structured how it extends beyond the liver and why New on Substack: (Free) $ARWR Understanding Arrowheads TRiM Platform A practical guide to how Arrowhead builds RNAi medicines at scale This is a long-form"
X Link 2026-01-05T08:41Z [----] followers, [----] engagements
"$ARWR Approval in Canada is leapfrogging competitor's TRYNGOLZA (IONS). REDEMPLO can be self administered at home $ARWR Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) https://t.co/QxlrbmkH8v $ARWR Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) https://t.co/QxlrbmkH8v"
X Link 2026-01-05T13:09Z [----] followers, [----] engagements
"$ARWR Interim obesity data are out. Looks very good to me. Let the market decide"
X Link 2026-01-06T12:37Z [----] followers, [----] engagements
"$ARWR Comparing WVE and ARWR data by grok from fredster at discord"
X Link 2026-01-06T12:53Z [----] followers, [----] engagements
"$ARWR One more from partimefriend at discord too"
X Link 2026-01-06T13:00Z [----] followers, [---] engagements
"$ARWR I remember James Hamilton saying that obesity tissue has liver like receptors. Now with ALK7 we have the proof of it Have in mind that delivering to the liver has been proven many times with several RNAi drugs approved"
X Link 2026-01-06T13:18Z [----] followers, [----] engagements
"$ARWR Best and fastest drug candidate maker in the World The Shinkansen of the pharmaceutical industry. We are leaving the train station NOW🎯🚀 Most important our TriM platform is very safe"
X Link 2026-01-06T17:17Z [----] followers, [----] engagements
"$ARWR More good News REDEMPLO APPROVAL IN CHINA"
X Link 2026-01-07T12:33Z [----] followers, [----] engagements
"$ARWR CEO: NMPA approval of REDEMPLO for FCS in China is another positive step and continues the strong momentum since launching in the U.S. in November [----]. We look forward to working with Sanofi an innovative global company with an established presence in China said Christopher Anzalone Ph.D. President and CEO at Arrowhead Pharmaceuticals. We are happy to report encouraging initial response from physicians and patients following FDA approval and launch in the U.S. last month. We intend to continue building on this rapid progress and anticipate additional commercial launches in [----] pending"
X Link 2026-01-07T12:41Z [----] followers, [---] engagements
"@LeftyT75 $ARWR Exactly why our company should be validated as a platform company. Once we have solved the tissue delivery specifications (liver muscle lung CNS adipose etc) it's easy and cheap scalable to dozens new drug candidates"
X Link 2026-01-10T08:24Z [----] followers, [---] engagements
"$ARWR Expanding at a fast pace Again [--] positions open - including summer intern and 3rd shift in manufacturing. https://arrowheadpharma.com/careers/job-openings/ https://arrowheadpharma.com/careers/job-openings/"
X Link 2026-01-11T07:42Z [----] followers, [----] engagements
"@BioBoyScout $ARWR Really impressed he did a very good job"
X Link 2026-01-12T20:11Z [----] followers, [---] engagements
"$ARWR Thx to Quantumup at Stocktwits Piper Sandler $ARWR's PT to $110 and reit'd at Overweight $IONS $WVE $RHHBY $REGN TEVA Piper Sandler said in its note: Arrowhead launched Redemplo for familial chylomicronemia syndrome (FCS) and we conservatively forecast sales of $8.4 million in FY:26 to grow to $41.6 million in FY:27. We are confident Arrowhead will report positive Phase III Redemplo data in severe hypertriglyceridemia in 3Q:26 with potential blockbuster label expansion in CY:27. Arrowhead reported impressive weight and fat loss data from the ongoing Phase I/II studies of ARO-INHBE and"
X Link 2026-01-13T13:31Z [----] followers, [---] engagements
"$ARWR Now [--] jobs open"
X Link 2026-01-13T13:47Z [----] followers, [---] engagements
"@grok @too_vez @Vivek4real_ It was always like that nothing new"
X Link 2026-01-28T12:07Z [----] followers, [--] engagements
"@joey_pots @RNAiAnalyst The $ARWR HBV-Deal will be BIG These negotiations take more time. Soon in this theater"
X Link 2017-10-19T12:58Z [----] followers, [--] engagements
"Next catalysts for $ARWR: IND AMG-890 IND AMG-1 both with milestones 💰 💰 big collaboration extension with $AMGN on multiple targets partnership with one other BP IND ARO-ENaC. so stay tuned"
X Link 2018-06-19T06:50Z [----] followers, [--] engagements
"$ARWR Still seeking an Alliance Manager on their website. Lets get him and make him busy with $JNJ $AMGN and NVS ROG et al Post $ALNY & their surprisingly modest $REGN deal attn rightfully pivots to Arrowheads 2nd gen TRiM platform (generally believed to have now surpassed Alnylams current platform efficacy). Powerful profitable alliances exist ( $JNJ $AMGN) w/elite BPs $ARWR got next. Post $ALNY & their surprisingly modest $REGN deal attn rightfully pivots to Arrowheads 2nd gen TRiM platform (generally believed to have now surpassed Alnylams current platform efficacy). Powerful profitable"
X Link 2019-04-09T03:08Z [----] followers, [--] engagements
"$ARWR +17% Today WS celebrates Chris Anzalone CEO of the last [--] years. His business model is unbelievable strong. Much better than little IONS $DRNA +5%- dispersal of resources partnerships will slow co to BP pace - and [--] from $ALNY +5%. JM gave away $10 bil for some peanuts"
X Link 2019-11-25T20:49Z [----] followers, [--] engagements
"$ARWR Thx Evolving123 on YMB. Good for $ARWR bulls bad for $IONS and $AKCA cult members"
X Link 2020-01-23T12:51Z [----] followers, [--] engagements
"$ARWR I hope these results are the new gold standard for any trial against this disease. Every competitor - $vrtx - has to do pre and after treatment biopsies. Endpoints are monomer and polymer reductions at least. $ARWR AROAAT: Dear FDA what's next We got: - 97% red. in intra-hepatic Z-AAT polymer - 95% red. in intra-hepatic total Z-AAT burden - 66%/58% red. circulating ALT+GGT levels resp. - Up to 26% improv. in FibroScan values And this after only [--] doses $ARWR AROAAT: Dear FDA what's next We got: - 97% red. in intra-hepatic Z-AAT polymer - 95% red. in intra-hepatic total Z-AAT burden -"
X Link 2020-09-18T08:20Z [----] followers, [--] engagements
"$ARWR VX [---] already a dead horse"
X Link 2020-11-02T20:50Z [----] followers, [--] engagements
"$ARWR Novo Nordisk to acquire $DRNA for $39 Congrats longs RNAi is hot - again No rumors leaked before"
X Link 2021-11-18T12:15Z [----] followers, [--] engagements
"@BioBoyScout $AMGN has [--] products on the market. Market cap of $ [---] billions. $NVS has [--] products on the market. Market cap of $ [---] billions $ALNY has [--] products on the market. Market cap of $ [--] billions. $ARWR RNAi TRiM"
X Link 2023-06-01T20:42Z [----] followers, [--] engagements
"RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi partnerships to come Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk. $310m u/f to $ALNY. https://t.co/ivn2hZ12wr Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension"
X Link 2023-07-24T05:25Z [----] followers, [----] engagements
"With this new partnership a BO of $ALNY by Novartis is off the table IMO $ARWR RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi partnerships to come RNAi is hot again. Novartis bought private RNAi firm DTx a week ago now Roche's partnership with $ALNY. Both Swiss Pharma giant's sold their RNAi business to $ARWR a few years back for pennies. That's how BP creates shareholder value More RNAi"
X Link 2023-07-24T12:38Z [----] followers, [----] engagements
"$ARWR Reports inducement grants for [--] new employees. New total is around [---]. Financing announcements soon (partnership or royalty deal). https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-inducement-grants-under-22 $ARWR reports inducement grants for [--] new employees. That brings us to about [---] employees. Expanding fast. https://t.co/aCHRNcXScS https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-inducement-grants-under-22 $ARWR reports inducement grants for [--] new employees. That brings us to"
X Link 2023-09-28T04:14Z [----] followers, [----] engagements
"$ARWR On October the 3rd the company announced to participate in a BMO fireside chat on October 10th. Still now link available on the website. Did they canceled it I expect a PR for the reason tomorrow"
X Link 2023-10-11T19:16Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals to Present New Phase [--] Clinical Data on Cardiometabolic Pipeline at AHA [----] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-new-phase-2-clinical-data https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-present-new-phase-2-clinical-data"
X Link 2023-11-02T11:32Z [----] followers, [----] engagements
"$ARWR CEO: "As we are able to provide better clarity relating to the sources and magnitude of new capital I believe a clear overhang in our stock may be removed." With $350 mil cash today and planned expenditures $600 millions in [----] problem has to be solved next [--] months"
X Link 2023-11-30T09:38Z [----] followers, [----] engagements
"@pawcio2009 Merry Christmas to you and your family you're my favorite at X for sure"
X Link 2023-12-24T20:41Z [----] followers, [---] engagements
"$ARWR $450 mil offering was surprising to me Shareh. since [----] I saw all RS 10:1 offerings stopping DPC great $4.8 bil JNJ-deal: stock down 30% . Market like this minor offering bc we didn't gave away our most valuable CVD-assets Apoc3/ANG3 -JNJ lesson learned"
X Link 2024-01-03T20:23Z [----] followers, [----] engagements
"$ARWR CC CFO about financing: "Even interest rates are higher the cost of debt is certainly lower than our cost of equity capital. It's an important part of non-dilutive financing". Exactly my view too. Our markets will be big giving e.g. 25% future gains of PlozaSiran is bad"
X Link 2024-02-10T10:38Z [----] followers, [----] engagements
"$ARWR We have a new website: What is new to me is that we have [--] - two - phase 3's with PlozaSiran FCS and Hypertriglyceridemia Is that what was talked on last CC Patients pool is becoming bigger and bigger"
X Link 2024-02-14T14:15Z [----] followers, [----] engagements
"@BioBoyScout $ARWR What could be the impact of that big increase of the patient pool"
X Link 2024-03-21T09:21Z [----] followers, [---] engagements
"$ARWR Love market short time thinking. Couldn't resist to buy another 50K shares. NDA's starting this year. Expect [--] NDA every year from now. Expanding label for Ploza- and ZodaSiran. Wealth is made by patience not trading"
X Link 2024-05-10T19:43Z [----] followers, [----] engagements
"$ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other lung cand. - dosing patients now. Just a matter of time market will recognize Vertex competitor. Cardio is absolute priority. Wouldn't surprise me to see vrtx partnering"
X Link 2024-05-21T12:03Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Presents New Phase [--] Data of Plozasiran in Patients with Mixed Hyperlipidemia https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-plozasiran"
X Link 2024-05-28T10:20Z [----] followers, [----] engagements
"$ARWR with every day we are getting more intrinsic value Arrowhead Pharmaceuticals Presents New Phase [--] Data of Zodasiran in Patients with Mixed Hyperlipidemia https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-zodasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-phase-2-data-zodasiran"
X Link 2024-05-29T09:36Z [----] followers, [----] engagements
"$ARWR Busy month again Data C3 Arrowhead Pharmaceuticals to Participate in Upcoming June [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-june-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-june-2024"
X Link 2024-05-31T11:37Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase [--] CAPITAN Cardiovascular Outcomes Trial https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-advance-rnai-based-plozasiran-phase-3 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-advance-rnai-based-plozasiran-phase-3"
X Link 2024-06-25T18:03Z [----] followers, [----] engagements
"$ARWR R&DDay pulmonary platform on July 16th. New data ARORAGE in asthma patients. Serum sRAGE up to 88% reduction and durable Wonderful safety profile. I remember an UBS analyst asking if 50% KD would be good enough. $ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other lung cand. - dosing patients now. Just a matter of time market will recognize Vertex competitor. Cardio is absolute priority. Wouldn't surprise me to see vrtx partnering $ARWR RAGE KD up to 88% + wonderful safety profile. NOW we've proven Lung platform in patients Two other"
X Link 2024-07-17T10:03Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals to Webcast Fiscal [----] Third Quarter Results on August [--] [----] https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-fiscal-2024-third-quarter https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-fiscal-2024-third-quarter"
X Link 2024-07-24T11:48Z [----] followers, [---] engagements
"$ARWR Its always good to take a step back and analyze. We will be a strong follower of Alnys success Besides the balance sheet my take is that CEO did a good job over the years. Im certain he will manage the balance sheet soon too"
X Link 2024-07-30T11:42Z [----] followers, [----] engagements
"$ARWR CC PALISADE phase [--] with PlozaSiran Need some help"
X Link 2024-09-04T10:21Z [----] followers, [----] engagements
"@Boarder31 @BioBoyScout I never pumped $ARWR I only expressed my vision of a future big biotech company"
X Link 2024-10-04T12:28Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals to Participate in Upcoming November [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-november-2024"
X Link 2024-11-04T12:54Z [----] followers, [---] engagements
"$ARWR Arrowhead Pharmaceuticals to Webcast [----] Fiscal Year End Results on November 26th https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-webcast-2024-fiscal-year-end-results"
X Link 2024-11-05T12:40Z [----] followers, [---] engagements
"$ARWR Months ago since CEO in public happy to hear him personally - first time ever at UBS Zrich He addressed honestly the big question market is waiting for a response: how do you pay for the big pipeline He was quite excited so deal soon with a Swiss giant NDA Nov24. $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp $ARWR ubs presentation credit tadmak: https://t.co/W29qCnZ9Lp"
X Link 2024-11-13T06:10Z [----] followers, [----] engagements
"$ARWR Great IDEA Big opportunity to reduce costs So let's stop [--] phase [--] PlozaSiran in patients with sHTG and Dyslipidemia bc our phase [--] in FCS (genetic and clinical diagnosed) patients was very successful My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead of one refusal to accept valid clinical results from other nations etc.). This stops patients from accessing promising therapies & raises prescription drug My #1 issue with FDA is that it erects unnecessary barriers to innovation (e.g. two replicate phase [--] studies instead"
X Link 2024-11-15T09:04Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase [--] Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-new-data-aha24-palisade-phase"
X Link 2024-11-18T12:43Z [----] followers, [---] engagements
"$ARWR After listening to fireside chat at Jeffries I look forward to hear about a pulmonary platform deal with RAGE MUC5AC and MMP7 in coming weeks. https://ir.arrowheadpharma.com/events-and-presentations https://ir.arrowheadpharma.com/events-and-presentations"
X Link 2024-11-20T09:32Z [----] followers, [----] engagements
"$ARWR RNAi and we are still attractive for partnering Our CEO @ArrowheadPharma was hated by many with this Partnership he will be loved again. If he delivers with a great launch of PlozaSiran next year he will be everybody's darling. Patience payed https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-global-license-and"
X Link 2024-11-26T13:00Z [----] followers, [----] engagements
"$ARWR I admit I was never a fan of Sarepta and their DMD-drugs. But to advance ARWR's candidates under this collaboration I see it very positive Our other BP partner's are slow walking partners. SRPT has big interests to go fast"
X Link 2024-11-26T13:34Z [----] followers, [---] engagements
"With [--] cand. deal $ARWR is eligible to receive dev. MS of between $110 mil and $410 mil per program and sales milestone payments of between $500 mil and $700 mil per PROGRAM. ARWR is also eligible to receive tiered royalties on commercial sales up to the low double digits💪💰💰"
X Link 2024-11-26T16:14Z [----] followers, [---] engagements
"$ARWR Verona WI manufac/testing fac. successfully completed requirements to manufacture GMP drug substance to support US trials+other countries+ recently successf. completed QPaudit which allows internally produc. drug substance to be used in support o clinic programs in EU/UK"
X Link 2024-11-26T21:13Z [----] followers, [----] engagements
"$ARWR Update SI"
X Link 2024-11-26T21:38Z [----] followers, [---] engagements
"$ARWR ZODASIRAN alive"
X Link 2024-11-26T21:40Z [----] followers, [---] engagements
"$ARWR Happy to see CVOT pushed back till more capital is available. TRiM platform machine is working hard to push more new candidates in clinic"
X Link 2024-11-26T21:59Z [----] followers, [----] engagements
"$ARWR Capital available [---] billion Cash burn planned for [----] is [---] million. Cash at the end of 2025: 1billion 💰💰"
X Link 2024-11-26T22:10Z [----] followers, [---] engagements
"$ARWR $SRPT My conclusions about risks and chances Summary of Programs under License and Collaboration Agreement Clinical Stage ARO-DUX4 which is designed to target the gene that encodes the DUX4 protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy type [--] currently dosing patients in a Phase 1/2 clinical study. ARO-DM1 which is designed to reduce expression of the dystrophia myotonica protein kinase or DMPK gene in skeletal muscle as a potential treatment for patients with type [--] myotonic dystrophy currently dosing patients in a Phase 1/2 clinical study."
X Link 2024-11-27T20:14Z [----] followers, [----] engagements
"$ARWR More good News from PlozaSiran at AHA and TRIG-Forum More and more evidence that PlozaSiran will be a blockbuster drug. CEO: once in a lifetime opportunity https://www.triglycerideforum.org https://www.triglycerideforum.org"
X Link 2024-11-28T11:29Z [----] followers, [----] engagements
"$ARWR Busy 2weeks Arrowhead Pharmaceuticals to Participate in Upcoming December [----] Conferences https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024 https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-participate-upcoming-december-2024"
X Link 2024-12-02T12:43Z [----] followers, [---] engagements
"$ARWR: I had some time on my hands and played around with some numbers after the great $SRPT - $ARWR deal I know it's very optimistic and certainly has some small errors but it's only about the macro and not the micro picture. CRAZY Numbers A lot of work for the Sarepta guys @ArrowheadPharma"
X Link 2024-12-05T11:23Z [----] followers, [---] engagements
"$ARWR Exactly and let's keep in mind that INHBE is a liver target candidate. The TRiM liver platform is x time successfully proven (AAT OlpaSiran PlozaSiran and ZodaSiran) Clinical results were even better than pre clinical results So I expect the same for INHBE. ALK7 is targeting adipose tissue and James Hamilton said on one of the last CC that adipose tissue "acts " like the liver tissue. Easy to target with RNAi Can't wait to see trial results in 2025"
X Link 2024-12-09T09:57Z [----] followers, [---] engagements
"$ARWR Developing siRNA for Neurodegenerative Diseases with very nice overview about RNAi and capabilities of TRiM platform https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187 https://ir.arrowheadpharma.com/static-files/af976827-088e-4926-912d-b6ca99422187"
X Link 2024-12-11T07:31Z [----] followers, [---] engagements
"$ARWR Title: PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) The APA/JPS/CAP/IAP [----] Joint Meeting Poster link: https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde https://ir.arrowheadpharma.com/static-files/18ed5e0f-61dc-4af6-81e3-bfd9ce021fde"
X Link 2024-12-11T07:42Z [----] followers, [---] engagements
"$ARWR 21st Global CVCT Forum Title: A Randomized Placebo-Controlled Phase [--] Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Data from subjects in an open-label extension trial - a Glimpse into [--] months results Presentation link: https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5 https://ir.arrowheadpharma.com/static-files/60c92ea0-beac-4d0b-9f25-8bfaa56179d5"
X Link 2024-12-11T07:50Z [----] followers, [---] engagements
"$ARWR Conclutions:"
X Link 2024-12-11T09:05Z [----] followers, [----] engagements
"$ARWR Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-interim-clinical-data-aro-cfb"
X Link 2024-12-11T12:32Z [----] followers, [----] engagements
"$ARWR James Hamilton M.D. MBA Chief of Discovery and Translational Medicine at Arrowhead. ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose levels. These interim results in healthy volunteers give us confidence in the potential of ARO-CFB as we seek to complete Part [--] of the study over the coming months and subsequently look ahead to Part [--] of the study in patients with immunoglobulin A nephropathy which is the most common glomerular disease worldwide"
X Link 2024-12-11T12:34Z [----] followers, [---] engagements
"The Swiss National Bank is lowering interest rates to 0.5% Inflation in Switzerland in November [----] was 0.7% compared to the same month last year. We live in the best country in the world bc we are not part of the EU but independent"
X Link 2024-12-12T09:21Z [----] followers, [---] engagements
"$ARWR PALISADE: A Phase [--] Study to Assess the Efficacy and Safety of Plozasiran in Adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32 https://ir.arrowheadpharma.com/static-files/57ab3dd8-1748-4a20-9c61-6b4ec05bac32"
X Link 2024-12-13T15:47Z [----] followers, [---] engagements
"$ARWR And here the poster. https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c https://ir.arrowheadpharma.com/static-files/575f46c5-a803-4c43-93a1-4497170d999c"
X Link 2024-12-13T15:48Z [----] followers, [---] engagements
"$ARWR Conclusions"
X Link 2024-12-13T15:51Z [----] followers, [----] engagements
"@BioBoyScout Ions without AP reduction label too $ARWR PlozaSiran had statistically significant AP reduction of 83%"
X Link 2024-12-20T14:21Z [----] followers, [---] engagements
"$ARWR Some People have questioned the manufacturing and labor facility at Verona. CEO just perfectly planned it In December [----] the facility is planned to be ready and certified. Thx - again and again - to coldlander at discord: "scheduled to allow for the manufacture of GMP drug substance at the facility which is currently anticipated to begin by December 2024." This facility could turn into a future powerhouse for $ARWR in the light of RNAi future. #AMGN #Novartis et. al. CEO is a visionary"
X Link 2024-12-22T21:25Z [----] followers, [----] engagements
"@pawcio2009 Happy new year to you and your family Thx for your work for the biotech community thx for your daily comments thx for your free honest and - politically - "incorrect" comments Love it"
X Link 2025-01-01T22:25Z [----] followers, [---] engagements
"$ARWR PlozaSiran: Assuming company filed for geno- AND phenotype FCS patients and NDA is accepted in a few days. Does this mean that FDA is ready to approve PlozaSiran for both patient population in Q2/2025 PlozaSiran did meet all endpoint's in phase [--] Incl. statistical reduction of acute pancreatitis of 83% After IONS inferior drug olezarsen (branded as Tryngolza) approval a few days ago approval of PlozaSiran is a no brainer. So the patient population for ARWR should be at least 10x the patient population of IONS IONS extreme price tag is $595'000"
X Link 2025-01-04T21:44Z [----] followers, [----] engagements
"$ARWR I may be wrong but IONS price tag of $595'000 for only genetic confirmed FCS patients without AP label is way too high. If you're the only seller of a new drug against FCS price might be OK. But with $ARWR superior drug (AP label dosing interval less drug more knock down better safety profile and maybe cheaper) coming on the market in just a few months patients and doctors may wait for PlozaSiran - I would wait for sure"
X Link 2025-01-05T11:14Z [----] followers, [---] engagements
"$ARWR Genetic confirmed Familial chylomicronemia syndrome (FCS) has an estimated prevalence of 1/300000 (ranging from 1/100000 to 1/1000000 in Europe and North America). Let's take one third of world's population [---] billion. That will give around [----] patients. Clinically confirmed - phenotype - patients are around tenfold more. Let's assume we get [--] % of genotype FCS patients and [--] % of phenotype FCS patients. Genotype is ultra orphan so price could be $450'000. Phenotype is orphan price could be $100'000. Results: Genotype: $1124955000 Phenotype: $1'666'000'000 This is just playing around"
X Link 2025-01-05T20:22Z [----] followers, [---] engagements
"$ARWR Don't forget that Severe hypercholesterolemia often defined as a LDL-C [---] mmol/L (193 mg/dL) confers 5-fold increased risk of developing ASCVD and is considered an indication for statin therapy in many national and international guidelines. Severe hypercholesterolemia affects 5% of the global population. Our [--] year phase [--] trial is almost fully enrolled. Readout in first have of [----]. sNDA soon afterwards"
X Link 2025-01-05T20:43Z [----] followers, [---] engagements
"$ARWR YES FDA accepts our first NDA Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome We would like to thank all Arrowhead employees and the investigators patients and caregivers who contributed to the PALISADE Phase [--] study of plozasiran in patients with genetically confirmed or clinically diagnosed FCS said Chris Anzalone Ph.D. President and CEO at Arrowhead. Plozasiran has achieved promising and consistent results in various patient populations representing multiple points on the spectrum"
X Link 2025-01-17T22:41Z [----] followers, [----] engagements
"GREAT deal between $ARWR and $SRPT is closed. Whats now (CEO at last CC): Now feel like all the pieces are in place to accelerate growth. We are confident that we will be ready for our potential first commercial launch in [----] provided we receive positive FDA approval. Strategy Balance sheet: See pinned tweet Cash runway extends into [----]. We will end CY25 with approx. $1.5 billion cash. In cardiometabolic area we're focusing resources (75%) as following: PlozaSiran is rapidly progressing toward commercial stage. NDA FDA accepted; PDUFA Nov. 18th We've begun leveraging outsourced resources"
X Link 2025-02-07T11:32Z [----] followers, [----] engagements
"@biomannn @Varro_Analytics TRiM their RNAi platform was introduced in [----] only. Now we have our first NDA of several more to come in coming years. This tells me that this company is becoming a big biotech company. Bigger than alny $ARWR"
X Link 2025-02-08T21:08Z [----] followers, [---] engagements
"$ARWR Confirmation💪💰💪💰 Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics Summary Financial Terms Upon closing Arrowhead receives a $500 millionupfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at $27.25 per share. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over [--] years. Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study of"
X Link 2025-02-10T14:07Z [----] followers, [----] engagements
"$ARWR JUST WOW Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity James Hamilton M.D. MBA Chief Medical Officer and Head of R&D. In preclinical studies in rodents and non-human primates ARO-ALK7 demonstrated dose-dependent and durable reductions in ALK7 mRNA expression in adipose tissue. Pharmacological studies in diet-induced obese mouse models demonstrate that ALK7 silencing in adipose tissue led to improved body composition with an approximate 50% reduction in fat mass with preservation of lean mass. Furthermore co-treatment of tirzepatide a GLP-1/GIP"
X Link 2025-02-25T12:36Z [----] followers, [----] engagements
"@yaireinhorn $ARWR has no RNA editing candidate We are leading the RNAi extra hepatic field and we have a best in class RNAi platform"
X Link 2025-03-17T20:15Z [----] followers, [---] engagements
"After today's SRPT disclosure of a patient's death on their gene therapy Elevidys I know why I like my RNAi platform company $ARWR so much RNAi is a natural occurring process in our body and therefore much lesser risky than a gene therapy. If there is a problem with RNAi - just stop taking the drug. I think also the market is looking at it that way. Sarepta's guidance for 2025: Doug Ingram president and chief executive officerSarepta Therapeutics. In [----] we intend to capitalize on our [----] achievements. In addition to [----] net product revenue guidance of$2.9 billionto$3.1 billion"
X Link 2025-03-18T19:44Z [----] followers, [----] engagements
"$ARWR Results from our annual meeting"
X Link 2025-03-19T10:26Z [----] followers, [---] engagements
"@ej23ny @BowTiedBiotech $ARWR AADT liver population is small Look at these numbers Big market Thanks to @BioBoyScout"
X Link 2025-03-19T11:13Z [----] followers, [---] engagements
"RNAi $ARWR $ALNY Label: https://t.co/dDBqG08LJN $ALNY Label: https://t.co/dDBqG08LJN"
X Link 2025-03-20T22:33Z [----] followers, [----] engagements
"$ARWR Market turmoil Irrational exaggeration in both directions Let's just keep cool and enjoy the last presentation about blockbuster PlozaSiran (Shasta [--] Muir) at: The American College of Cardiology (ACC) [----] March 29-2025 Chicago Illinois Turmoil at the new FDA bc of DOGE Not me I'm very optimistic that we will get our approval before PDUFA date November [--] [----] There are so many ppl working at the FDA just waiting to prove their efficiency and competence to the new administration"
X Link 2025-04-08T14:54Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing